Allergic antigens and their epitopes

Abstract

To provide novel antigens of allergies to soybeans, methods and kits for diagnosing allergies to soybeans, pharmaceutical compositions comprising the antigens, soybeans or processed soybean products in which the antigens have been eliminated, and testers for determining the presence or absence of soybean antigens in subjects.SOLUTION: The present invention provides polypeptides that specifically bind to the IgE antibody of allergy patients, the polypeptides comprising specific amino acid sequences, kits for diagnosing allergies, comprising at least one of the polypeptides, and compositions for diagnosing allergies, comprising at least one of the polypeptides as an antigen.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a novel antigen for soybean allergy. The present invention also relates to a diagnostic kit, diagnostic composition, and diagnostic method for soybean allergy. The present invention also relates to a pharmaceutical composition containing the antigen, and soybeans or soybean processed products in which the antigen has been removed or reduced. The present invention further relates to a tester for determining the presence or absence of a soybean antigen in a subject.

[0002] The present invention also relates to a polypeptide comprising an epitope of an allergen.The present invention also relates to an allergy diagnostic kit, diagnostic composition, and diagnostic method comprising said polypeptide.The present invention also relates to a pharmaceutical composition comprising said polypeptide, and a food ingredient or processed food product in which an antigen comprising said polypeptide has been removed or reduced, or in which said polypeptide has been cleaved or removed.The present invention further relates to a method for producing a processed food product in which said antigen has been removed or reduced.The present invention still further relates to a tester for determining the presence or absence of an antigen comprising said polypeptide in a target object. [Background technology]

[0003] IgE antibodies specific to specific antigens are produced in the blood and tissues of allergic patients, and the physiological consequences of the interaction between these IgE antibodies and specific antigens result in an allergic reaction.

[0004] In conventional allergy test reagents, antigen reagents are often prepared by simply grinding food or ingredients that are allergen candidates (Patent Document 1). Thus, conventional antigen reagents do not necessarily contain a single specific antigen protein (allergen component) that causes an allergic reaction, but contain multiple protein components. Therefore, the content of each allergen component in conventional antigen reagents varies. Therefore, a positive reaction in an allergy test could only be detected if, among the many proteins contained in a conventional antigen reagent, a protein whose content exceeds the threshold for determining a positive reaction in binding with IgE antibodies is an allergen component. Conversely, for patients whose IgE antibodies bind to allergen components present in small amounts in foods, etc., a positive reaction could not be determined even with conventional allergy test reagents, and diagnostic efficiency was not sufficiently high.

[0005] Furthermore, the symptoms and severity of allergic reactions do not necessarily correlate with the amount of allergen component present. Even if a patient's IgE antibodies react to trace amounts of allergen components present in a food or ingredient that is a potential allergen, they may cause allergic symptoms or contribute to the severity of the symptoms.

[0006] Attempts are being made to improve diagnostic efficiency by examining IgE antibodies against each component that makes up the crude antigen, thereby distinguishing between sensitization that directly leads to diagnosis and sensitization based on cross-reactivity with panallergens, etc. Currently, eight soybean allergens are registered with the World Health Organization / International Union for Immunology (WHO / IUIS).

[0007] However, to improve the reliability of allergy testing, it is necessary to comprehensively identify allergen components in candidate foods and ingredients, but the patient detection rate by measuring the above allergen components is still insufficient. Identifying new soy allergens is extremely important not only to improve the accuracy of diagnostic drugs, but also as targets for hypoallergenic foods and therapeutic drugs.

[0008] On the other hand, various methods have been investigated for separating and purifying proteins and nucleic acids from cell extracts, etc. Dialysis and centrifugation using salt concentration are examples of such methods.

[0009] In addition, many purification methods that utilize the charge of protein or nucleic acid residues or differences in molecular weight are being investigated. Examples of purification methods that utilize charge include column chromatography using ion exchange resins and isoelectric focusing. Examples of purification methods that utilize differences in molecular weight include centrifugation, column chromatography using molecular weight sieves, and SDS-PAGE (dodecane-dioxide-polymerization gel electrophoresis). Examples include sodium silyl sulfate-polyacrylamide gel electrophoresis.

[0010] In recent years, two-dimensional electrophoresis, in which isoelectric focusing is performed in the first dimension and SDS-PAGE is performed in the second dimension, has been used as a method for separating and purifying various proteins from a small amount of sample. The applicants have previously developed two-dimensional electrophoresis methods with high resolution (Patent Documents 2 to 5).

[0011] Allergen-specific IgE antibodies recognize and bind to epitopes, which are specific amino acid sequences in allergen components. However, although there are a few examples in which epitopes have been analyzed for allergen components (Non-Patent Document 1), the current situation is extremely limited. Furthermore, there are currently no allergy diagnostic kits on the market that utilize polypeptides containing epitopes. [Prior art documents] [Patent documents]

[0012] [Patent Document 1] Patent Publication No. 2002-286716 [Patent Document 2] Patent Publication No. 2011-33544 [Patent Document 3] Patent Publication No. 2011-33546 [Patent Document 4] Patent Publication No. 2011-33547 [Patent Document 5] Patent Publication No. 2011-33548 [Non-patent literature]

[0013] [Non-Patent Document 1] Matsuo, H., et al., J. Biol. Chem., (2004), Vol.279, No.13, pp.12135-12140 [Non-patent document 2] Zhao, L., et al., PLoS One. 2017 Aug 11; 12(8):e0182935. doi: 10.1371 / journal.pone.0182935. eCollection 2017. [Non-patent document 3] Cong, Y., et al., J Dairy Sci. 2013; 96(11):6870-6. doi: 10.3168 / jds.2013-6880. Epub 2013 Sep 12. [Non-patent document 4] Beezhold, DH, et al., J Allergy Clin Immunol. 2001 Jun; 107(6):1069-76. Summary of the Invention [Problem to be solved by the invention]

[0014] The present invention provides a novel antigen for soybean allergy. The present invention also provides a method and a diagnostic kit for diagnosing soybean allergy. The present invention also provides a pharmaceutical composition containing the antigen, and soybeans or soybean processed products in which the antigen has been removed or reduced. The present invention further provides a tester for determining the presence or absence of a soybean antigen in a subject.

[0015] The present invention also provides a polypeptide comprising an epitope of an allergen. The present invention also provides a diagnostic kit, a diagnostic composition, and a diagnostic method for allergies. The present invention also provides a pharmaceutical composition comprising the polypeptide, and a food material or processed food product from which an antigen comprising the polypeptide has been removed or reduced, or from which the polypeptide has been cleaved or removed. The present invention further relates to a method for producing a processed food product in which the antigen has been removed or reduced.The present invention still further provides a tester for determining the presence or absence of an antigen comprising the polypeptide in a target object. [Means for solving the problem]

[0016] In order to solve the above problems, the present inventors have conducted extensive research into identifying the antigens that cause allergies. As a result, they have succeeded in identifying a novel antigen that specifically binds to IgE antibodies in the serum of allergic patients. Based on this finding, the present invention has been completed.

[0017] That is, in one aspect, the present invention may be as follows.

[0018] [1] A diagnostic kit for soybean allergy, comprising at least one of the following proteins (1α) to (55α): (1α)(1αA1) endoplasmin homolog isoform X2 or a mutant thereof, which is any one of the following proteins (1αA1-a) to (1αA1-e): (1αA1-a) a protein comprising the amino acid sequence of SEQ ID NO: 70 in which one or several amino acids are deleted, substituted, inserted or added; (1αA1-b) a protein comprising an amino acid sequence having 70% or more identity to the amino acid sequence shown in SEQ ID NO: 70; (1αA1-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 69 have been deleted, substituted, inserted, or added; (1αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 69; or (1αA1-e) a protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 69; (1αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 71 to 87; (1αA2) endoplasmin homolog isoform X2 or a mutant thereof, which is any one of the following proteins (1αA2-a) to (1αA2-e): (1αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 89 in which one or several amino acids are deleted, substituted, inserted, or added; (1αA2-b) a protein comprising an amino acid sequence having 70% or more identity to the amino acid sequence shown in SEQ ID NO: 89; (1αA2-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 88 have been deleted, substituted, inserted, or added; (1αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 88; or (1αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 88; or (1αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 90 to 104; (2α)(2αA1) heat shock cognate protein 80 or a mutant thereof, Any of the proteins (2αA1-a) to (2αA1-e): (2αA1-a) a protein comprising the amino acid sequence of SEQ ID NO: 106 in which one or several amino acids are deleted, substituted, inserted or added; (2αA1-b) a protein comprising an amino acid sequence having 70% or more identity to the amino acid sequence shown in SEQ ID NO: 106; (2αA1-c) one or several nucleotides are deleted or substituted in SEQ ID NO: 105, a protein containing an amino acid sequence encoded by the inserted or added nucleotide sequence; (2αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 105; or (2αA1-e) a protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 105; (2αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 107 to 120; (2αA2) heat shock protein 90-1 or a mutant thereof, Any of the proteins a) to (2αA2-e): (2αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 122 in which one or several amino acids are deleted, substituted, inserted, or added; (2αA2-b) a protein comprising an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 122; (2αA2-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 121 have been deleted, substituted, inserted, or added; (2αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 121; or (2αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 121; or (2αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 123 to 137; (2αA3) hypothetical protein GLYMA_02G302500 or a variant thereof, which is any one of the following proteins (2αA3-a) to (2αA3-e): (2αA3-a) a protein comprising the amino acid sequence of SEQ ID NO: 139 in which one or several amino acids are deleted, substituted, inserted, or added; (2αA3-b) a protein comprising an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 139; (2αA3-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 138 have been deleted, substituted, inserted, or added; (2αA3-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 138; or (2αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 138; or (2αB3) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 140 to 153; (4α)(4αA)embryo-specific urease isoform X1 or a mutant thereof, Any of the proteins (4αA-a) to (4αA-e): (4αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 155 in which one or several amino acids are deleted, substituted, inserted or added; (4αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 155; (4αA-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 154 have been deleted, substituted, inserted, or added; (4αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 154; or (4αA-e) Amino acids encoded by nucleic acids that hybridize under stringent conditions with nucleic acids consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 154 a protein comprising the sequence; or (4αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 156 and 157; (5α)(5αA)alpha-1,4 glucan phosphorylase L isozyme, chloroplastic / amyloplastic or a mutant thereof, which is any one of the following proteins (5αA-a) to (5αA-e): (5αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 159 in which one or several amino acids are deleted, substituted, inserted or added; (5αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 159; (5αA-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 158 have been deleted, substituted, inserted, or added; (5αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 158; or (5αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 158; or (5αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 160 and 161; (6α)(6αA1)aconitate hydratase 1 or a mutant thereof, Any of the proteins 1-a) to (6αA1-e): (6αA1-a) a protein comprising the amino acid sequence of SEQ ID NO: 163 in which one or several amino acids are deleted, substituted, inserted, or added; (6αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence shown in SEQ ID NO: 163; (6αA1-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 162 have been deleted, substituted, inserted, or added; (6αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 162; or (6αA1-e) a protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 162; (6αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 164 to 167; or (6αA2)aconitate hydratase 1 or a mutant thereof, Any of the following proteins: (6αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 169 in which one or several amino acids are deleted, substituted, inserted, or added; (6αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 169; (6αA2-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 168 have been deleted, substituted, inserted, or added; (6αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 168; or (6αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 168; or (6αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 170 to 172; (7α)(7αA)methionine synthase or a mutant thereof, ) to (7αA-e) proteins: (7αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 174 in which one or several amino acids are deleted, substituted, inserted, or added; (7αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 174; (7αA-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 173 have been deleted, substituted, inserted, or added; (7αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 173; or (7αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 173; or (7αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 175 to 187; (8α)(8αA) transketolase, chloroplastic or a mutant thereof, which is any one of the following proteins (8αA-a) to (8αA-e): (8αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 189 in which one or several amino acids are deleted, substituted, inserted or added; (8αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 189; (8αA-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 188 have been deleted, substituted, inserted, or added; (8αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 188; or (8αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 188; or (8αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 190 to 199; (9α)(9αA)lysine-tRNA ligase, cytoplasmic-like isoform X2 or its mutants Any of the following proteins (9αA-a) to (9αA-e): (9αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 201 in which one or several amino acids are deleted, substituted, inserted or added; (9αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 201; (9αA-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 200 have been deleted, substituted, inserted, or added; (9αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence shown in SEQ ID NO: 200; or (9αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 200; or (9αB) a protein comprising the amino acid sequence set forth in SEQ ID NO: 202; (10α)(10αA1)chaperonin CPN60-2, mitochondrial or a mutant thereof , any of the following proteins (10αA1-a) to (10αA1-e): (10αA1-a) a protein comprising the amino acid sequence of SEQ ID NO: 204 in which one or several amino acids are deleted, substituted, inserted or added; (10αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence shown in SEQ ID NO: 204; (10αA1-c) One or several nucleotides are deleted or substituted in SEQ ID NO: 203 a protein comprising an amino acid sequence encoded by the inserted or added nucleotide sequence; (10αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 203; or (10αA1-e) a protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 203; (10αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 205 to 218; (10αA2)chaperonin CPN60-2, mitochondrial-like isoform X1 or its mutants Any of the following proteins (10αA2-a) to (10αA2-e): (10αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 220 in which one or several amino acids are deleted, substituted, inserted or added; (10αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 220; (10αA2-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 219 have been deleted, substituted, inserted, or added; (10αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 219; or (10αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 219; or (10αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 221 to 231; (11α)(11αA) polyadenylate-binding protein 8 isoform X3 or a mutant thereof, which is any one of the following proteins (11αA-a) to (11αA-e): (11αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 233 in which one or several amino acids are deleted, substituted, inserted, or added; (11αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 233; (11αA-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 232 have been deleted, substituted, inserted, or added; (11αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 232; or (11αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 232; or (11αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 234 to 237; (12α)(12αA)pyrophosphate-fructose 6-phosphate 1-phosphotransferase subunit alpha-like or a mutant thereof, which is any one of the following proteins (12αA-a) to (12αA-e): (12αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 239 in which one or several amino acids are deleted, substituted, inserted or added; (12αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 239; (12αA-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 238 have been deleted, substituted, inserted, or added; (12αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 238; or (12αA-e) A base sequence complementary to the base sequence shown in SEQ ID NO: 238 a protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid that is (12αB) a protein comprising the amino acid sequence set forth in SEQ ID NO: 240; A (13α)(13αA1) protein disulfide isomerase-like protein precursor or a mutant thereof, which is any one of the following proteins (13αA1-a) to (13αA1-e): (13αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 242 in which one or several amino acids are deleted, substituted, inserted or added; (13αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 242; (13αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 241 have been deleted, substituted, inserted, or added; (13αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 241; or (13αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 241; (13αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 243 to 252; (13αA2) protein disulfide-isomerase or a mutant thereof, Any of the proteins αA2-a) to (13αA2-e): (13αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 254 in which one or several amino acids are deleted, substituted, inserted or added; (13αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 254; (13αA2-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 253 have been deleted, substituted, inserted, or added; (13αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 253; or (13αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 253; or (13αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 255 to 278; (14α)(14αA1)V-type proton ATPase subunit B2 or a mutant thereof, which is any one of the following proteins (14αA1-a) to (14αA1-e): (14αA1-a) a protein comprising the amino acid sequence of SEQ ID NO: 280 in which one or several amino acids are deleted, substituted, inserted or added; (14αA1-b) a protein comprising an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 280; (14αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 279 have been deleted, substituted, inserted, or added; (14αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 279; or (14αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 279; (14αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 281 to 284; (14αA2) V-type proton ATPase subunit B2 or a mutant thereof, Any of the proteins 14αA2-a) to (14αA2-e): (14αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 286 in which one or several amino acids are deleted, substituted, inserted or added; (14αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 286; (14αA2-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 285 have been deleted, substituted, inserted, or added; (14αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 285; or (14αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 285; or (14αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 287 to 289; (15,16α)(15,16αA1)UTP-glucose-1-phosphate uridylyltransferase or a variant thereof, which is any one of the following proteins (15,16αA1-a) to (15,16αA1-e): (15,16αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 291 in which one or several amino acids are deleted, substituted, inserted or added; (15,16αA1-b) a protein containing an amino acid sequence that has 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 291; (15,16αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 290 have been deleted, substituted, inserted, or added; (15,16αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 290; or (15,16αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 290; (15,16αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 292 to 304; (15,16αA2) hypothetical protein GLYMA_02G241100 or a variant thereof, which is any one of the following proteins (15,16αA2-a) to (15,16αA2-e): (15,16αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 306 in which one or several amino acids are deleted, substituted, inserted or added; (15,16αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 306; (15,16αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 305 have been deleted, substituted, inserted, or added; (15,16αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 305; or (15,16αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 305; or (15,16αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 307 to 318; (17α)(17αA1)guanosine nucleotide diphosphate dissociation inhibitor 2 or a mutant thereof, which is any one of the following (17αA1-a) to (17αA1-e): Protein: (17αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 320 in which one or several amino acids are deleted, substituted, inserted or added; (17αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 320; (17αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 319 have been deleted, substituted, inserted, or added; (17αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 319; or (17αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 319; (17αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 321 to 325; (17αA2)rab GDP dissociation inhibitor alpha-like or a variant thereof, Any of the following proteins (17αA2-a) to (17αA2-e): (17αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 327 in which one or several amino acids are deleted, substituted, inserted or added; (17αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 327; (17αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 326 have been deleted, substituted, inserted, or added; (17αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 326; or (17αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 326; or (17αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 328 to 332; (18α)(18αA)hypothetical protein GLYMA_10G028300 or a variant thereof, which is any one of the following proteins (18αA-a) to (18αA-e): (18αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 334 in which one or several amino acids are deleted, substituted, inserted or added; (18αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 334; (18αA-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 333 have been deleted, substituted, inserted, or added; (18αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 333; or (18αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 333; or (18αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 335 to 339; (19α)(19αA) sucrose binding protein homolog S-64 or a variant thereof, which is any one of the following proteins (19αA-a) to (19αA-e): (19αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 341 in which one or several amino acids are deleted, substituted, inserted or added; (19αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 341; (19αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 340 have been deleted, substituted, inserted, or added; (19αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 340; or (19αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 340; or (19αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 342 to 346; (25α)(25αA1) succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial or a mutant thereof, which is any one of the following (25αA1-a) to (25αA1-e): Any protein: (25αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 348 in which one or several amino acids are deleted, substituted, inserted or added; (25αA1-b) a protein containing an amino acid sequence that has 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 348; (25αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 347 have been deleted, substituted, inserted, or added; (25αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 347; or (25αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 347; (25αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 349 to 356; (25αA2)succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial or is a mutant thereof, and is any one of the following proteins (25αA2-a) to (25αA2-e): (25αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 358 in which one or several amino acids are deleted, substituted, inserted or added; (25αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 358; (25αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 357 have been deleted, substituted, inserted, or added; (25αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 357; or (25αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 357; or (25αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 359 to 365; (26α)(26αA1)phosphoglycerate kinase, cytosolic or a mutant thereof, which is any one of the following proteins (26αA1-a) to (26αA1-e): (26αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 367 in which one or several amino acids are deleted, substituted, inserted or added; (26αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 367; (26αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 366 have been deleted, substituted, inserted, or added; (26αA1-d) A base sequence having 70% or more identity with the base sequence shown in SEQ ID NO: 366 a protein comprising the amino acid sequence encoded by the sequence; or (26αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 366; (26αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 368 to 382; (26αA2) phosphoglycerate kinase, cytosolic or a mutant thereof, which is any one of the following proteins (26αA2-a) to (26αA2-e): (26αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 384 in which one or several amino acids are deleted, substituted, inserted or added; (26αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 384; (26αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 383 have been deleted, substituted, inserted, or added; (26αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 383; or (26αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 383; (26αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 385 to 392; (26αA3) phosphoglycerate kinase, cytosolic or a mutant thereof, which is any one of the following proteins (26αA3-a) to (26αA3-e): (26αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 394 in which one or several amino acids are deleted, substituted, inserted or added; (26αA3-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 394; (26αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 393 have been deleted, substituted, inserted, or added; (26αA3-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 393; or (26αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 393; or (26αB3) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 395 to 409; (27α)(27αA1) alcohol dehydrogenase 1 or a variant thereof, Any of the proteins 27αA1-a) to (27αA1-e): (27αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 411 in which one or several amino acids are deleted, substituted, inserted or added; (27αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 411; (27αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 410 have been deleted, substituted, inserted, or added; (27αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 410; or (27αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 410; (27αB1) At least one amino acid sequence selected from the group consisting of SEQ ID NOs: 412 to 416 Proteins containing at least one; (27αA2) alcohol dehydrogenase 1 or a mutant thereof, Any of the proteins 2-a) to (27αA2-e): (27αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 418 in which one or several amino acids are deleted, substituted, inserted or added; (27αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 418; (27αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 417 have been deleted, substituted, inserted, or added; (27αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 417; or (27αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 417; (27αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 419 and 420; (27αA3) alcohol dehydrogenase 1-like or a mutant thereof, which is any one of the following proteins (27αA3-a) to (27αA3-e): (27αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 422 in which one or several amino acids are deleted, substituted, inserted or added; (27αA3-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 422; (27αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 421 have been deleted, substituted, inserted, or added; (27αA3-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 421; or (27αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 421; or (27αB3) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 423 to 427; (28α)(28αA)35 kDa seed maturation protein isoform X1 or its mutants and any one of the following proteins (28αA-a) to (28αA-e): (28αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 429 in which one or several amino acids are deleted, substituted, inserted or added; (28αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 429; (28αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 428 have been deleted, substituted, inserted, or added; (28αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 428; or (28αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 428; or (28αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 430 to 433; (29-33α)(29-33αA1) glyceraldehyde-3-phosphate dehydrogenase isoform X1 or a mutant thereof, Any of the proteins in 1-e): (29-33αA1-a) One or several amino acids are deleted or replaced in SEQ ID NO: 435 proteins containing substituted, inserted or added amino acid sequences; (29-33αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 435; (29-33αA1-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 434 have been deleted, substituted, inserted, or added; (29-33αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 434; or (29-33αA1-e) a protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 434; (29-33αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 436 to 439; (29-33αA2)glyceraldehyde-3-phosphate dehydrogenase, cytosolic or its A mutant of any of the following proteins (29-33αA2-a) to (29-33αA2-e): (29-33αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 441 in which one or several amino acids are deleted, substituted, inserted or added; (29-33αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 441; (29-33αA2-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 440 have been deleted, substituted, inserted, or added; (29-33αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 440; or (29-33αA2-e) a protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 440; (29-33αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 442 to 445; (29-33αA3) uncharacterized protein LOC100782924 or a mutant thereof, which is any one of the following proteins (29-33αA3-a) to (29-33αA3-e): (29-33αA3-a) a protein comprising the amino acid sequence of SEQ ID NO: 447 in which one or several amino acids are deleted, substituted, inserted or added; (29-33αA3-b) a protein containing an amino acid sequence that has 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 447; (29-33αA3-c) a protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 446 have been deleted, substituted, inserted, or added; (29-33αA3-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 446; or (29-33αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 446; or (29-33αB3) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 448 to 451; (34α)(34αA1) Bifunctional UDP-glucose 4-epimerase and UDP-xylose 4-epimerase 1-like or a variant thereof, which is any one of the following proteins (34αA1-a) to (34αA1-e): (34αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 453 in which one or several amino acids are deleted, substituted, inserted, or added; (34αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 453; (34αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 452 have been deleted, substituted, inserted, or added; (34αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 452; or (34αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 452; (34αB1) a protein comprising the amino acid sequence set forth in SEQ ID NO: 454; (34αA2) uncharacterized protein LOC100803483 or a mutant thereof, which is any one of the following proteins (34αA2-a) to (34αA2-e): (34αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 456 in which one or several amino acids are deleted, substituted, inserted or added; (34αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 456; (34αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 455 have been deleted, substituted, inserted, or added; (34αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 455; or (34αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 455; or (34αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 457 and 458; (35α)(35αA1) elongation factor 1-alpha or a variant thereof, Any of the proteins (35αA1-a) to (35αA1-e): (35αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 460 in which one or several amino acids are deleted, substituted, inserted or added; (35αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 460; (35αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 459 have been deleted, substituted, inserted, or added; (35αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 459; or (35αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 459; (35αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 461 to 466; (35αA2) elongation factor 1-alpha or a variant thereof, Any of the proteins A2-a) to (35αA2-e): (35αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 468 in which one or several amino acids are deleted, substituted, inserted or added; (35αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 468; (35αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 467 have been deleted, substituted, inserted, or added; (35αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 467; or (35αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 467; (35αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 469 to 471; (35αA3) elongation factor-1A isoform X1 or a mutant thereof, Any of the proteins 5αA3-a) to (35αA3-e): (35αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 473 in which one or several amino acids are deleted, substituted, inserted or added; (35αA3-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 473; (35αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 472 have been deleted, substituted, inserted, or added; (35αA3-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 472; or (35αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 472; or (35αB3) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 474 to 477; (36,37α)(36,37αA1) seed maturation protein PM34 or a mutant thereof, which is any one of the following proteins (36,37αA1-a) to (36,37αA1-e): (36,37αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 479 in which one or several amino acids are deleted, substituted, inserted or added; (36,37αA1-b) A protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 479; (36,37αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 478 have been deleted, substituted, inserted, or added; (36,37αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 478; or (36,37αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 478; (36,37αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 480 to 483; (36,37αA2) uncharacterized protein LOC100809384 or a mutant thereof, which is any one of the following proteins (36,37αA2-a) to (36,37αA2-e): (36,37αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 485 in which one or several amino acids are deleted, substituted, inserted or added; (36,37αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 485; (36,37αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 484 have been deleted, substituted, inserted, or added; (36,37αA2-d) 70% or more identity with the nucleotide sequence shown in SEQ ID NO: 484 a protein comprising an amino acid sequence encoded by the nucleotide sequence of (36,37αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 484; (36,37αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 486 and 487; (36,37αA3) hypothetical protein GLYMA_10G155300 or a variant thereof, which is any one of the following proteins (36,37αA3-a) to (36,37αA3-e): (36,37αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 489 in which one or several amino acids are deleted, substituted, inserted or added; (36,37αA3-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 489; (36,37αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 488 have been deleted, substituted, inserted, or added; (36,37αA3-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 488; or (36,37αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 488; or (36,37αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 490 to 493; (38α)(38αA)seed biotin-containing protein SBP65-like isoform X1 or a mutant thereof, which is any one of the following proteins (38αA-a) to (38αA-e): (38αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 495 in which one or several amino acids are deleted, substituted, inserted or added; (38αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 495; (38αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 494 have been deleted, substituted, inserted, or added; (38αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 494; or (38αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 494; or (38αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 496 to 513; (39α)(39αA)ATP synthase subunit O, mitochondrial-like, or a mutant thereof, which is any one of the following proteins (39αA-a) to (39αA-e): (39αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 515 in which one or several amino acids are deleted, substituted, inserted or added; (39αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 515; (39αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 514 have been deleted, substituted, inserted, or added; (39αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 514; or (39αA-e) An amino acid encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 514 a protein containing a nucleic acid sequence; or (39αB) a protein comprising the amino acid sequence set forth in SEQ ID NO: 516; (40,56α)(40,56αA)P24 oleosin isoform A or a variant thereof, Any of the following proteins (40,56αA-a) to (40,56αA-e): (40,56αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 518 in which one or several amino acids are deleted, substituted, inserted or added; (40,56αA-b) A protein containing an amino acid sequence that has 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 518; (40,56αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 517 have been deleted, substituted, inserted or added; (40,56αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 517; or (40,56αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 517; or (40,56αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 519 and 520; (41α)(41αA)uncharacterized protein At3g49720-like isoform X2 or its A mutant of any of the following proteins (41αA-a) to (41αA-e): (41αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 522 in which one or several amino acids are deleted, substituted, inserted or added; (41αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 522; (41αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 521 have been deleted, substituted, inserted, or added; (41αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 521; or (41αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 521; or (41αB) a protein comprising the amino acid sequence set forth in SEQ ID NO: 523; (42,43α)(42,43αA1) superoxide dismutase [Mn], mitochondrial, or a mutant thereof, which is any one of the following proteins (42,43αA1-a) to (42,43αA1-e): (42,43αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 525 in which one or several amino acids are deleted, substituted, inserted or added; (42,43αA1-b) A protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 525; (42,43αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 524 have been deleted, substituted, inserted, or added; (42,43αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 524; or (42,43αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 524; (42, 43αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 526 to 531; (42,43αA2) hypothetical protein GLYMA_04G221300 or a variant thereof, which is any one of the following proteins (42,43αA2-a) to (42,43αA2-e): : (42,43αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 533 in which one or several amino acids are deleted, substituted, inserted or added; (42,43αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 533; (42,43αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 532 have been deleted, substituted, inserted, or added; (42,43αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 532; or (42,43αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 532; or (42, 43αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 534 to 539; (45α)(45αA1)uncharacterized protein LOC100499771 or a mutant thereof, which is any one of the following proteins (45αA1-a) to (45αA1-e): (45αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 541 in which one or several amino acids are deleted, substituted, inserted or added; (45αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 541; (45αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 540 have been deleted, substituted, inserted, or added; (45αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 540; or (45αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 540; (45αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 542 to 545; (45αA2) hypothetical protein GLYMA_09G192800 or a variant thereof, which is any one of the following proteins (45αA2-a) to (45αA2-e): (45αA2-a) a protein comprising the amino acid sequence of SEQ ID NO: 547 in which one or several amino acids are deleted, substituted, inserted or added; (45αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 547; (45αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 546 have been deleted, substituted, inserted, or added; (45αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 546; or (45αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 546; or (45αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 548 to 551; (46α)(46αA) seed maturation protein PM22 or a mutant thereof, which is any one of the following proteins (46αA-a) to (46αA-e): (46αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 553 in which one or several amino acids are deleted, substituted, inserted or added; (46αA-b) an amino acid sequence having 70% or more identity with the amino acid sequence shown in SEQ ID NO: 553 Proteins containing amino acid sequences; (46αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 552 have been deleted, substituted, inserted, or added; (46αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 552; or (46αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 552; or (46αB) a protein comprising the amino acid sequence set forth in SEQ ID NO: 554; (47α)(47αA1) eukaryotic translation initiation factor 5A-2 or its variants A variant of any of the following proteins (47αA1-a) to (47αA1-e): (47αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 556 in which one or several amino acids are deleted, substituted, inserted or added; (47αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 556; (47αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 555 have been deleted, substituted, inserted, or added; (47αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 555; or (47αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 555; (47αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 557 and 558; (47αA2) uncharacterized protein LOC100305510 or a mutant thereof, which is any one of the following proteins (47αA2-a) to (47αA2-e): (47αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 560 in which one or several amino acids are deleted, substituted, inserted or added; (47αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 560; (47αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 559 have been deleted, substituted, inserted, or added; (47αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 559; or (47αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 559; or (47αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 561 to 563; (48α)(48αA)uncharacterized protein LOC100306570 or a mutant thereof, which is any one of the following proteins (48αA-a) to (48αA-e): (48αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 565 in which one or several amino acids are deleted, substituted, inserted or added; (48αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 565; (48αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 564 have been deleted, substituted, inserted, or added; (48αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 564; or (48αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 564; or (48αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 566 to 570; (50α)(50αA)uncharacterized protein LOC100813859 or a variant thereof, which is any one of the following proteins (50αA-a) to (50αA-e): (50αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 572 in which one or several amino acids are deleted, substituted, inserted or added; (50αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 572; (50αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 571 have been deleted, substituted, inserted, or added; (50αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 571; or (50αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 571; or (50αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 573 to 576; (51α)(51αA)14-3-3-like protein or a mutant thereof, Any of the proteins Aa) to (51αA-e): (51αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 578 in which one or several amino acids are deleted, substituted, inserted or added; (51αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 578; (51αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 577 have been deleted, substituted, inserted, or added; (51αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 577; or (51αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 577; or (51αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 579 to 582; (52α)(52αA)probable fructokinase-4 or a variant thereof, Any of the proteins 2αA-a) to (52αA-e): (52αA-a) a protein comprising the amino acid sequence of SEQ ID NO: 584 in which one or several amino acids are deleted, substituted, inserted or added; (52αA-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 584; (52αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 583 have been deleted, substituted, inserted, or added; (52αA-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 583; or (52αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 583; or (52αB) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 585 to 588; (53α)(53αA1)triosephosphate isomerase isoform X1 or a mutant thereof, which is any one of the following proteins (53αA1-a) to (53αA1-e): (53αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 590 in which one or several amino acids are deleted, substituted, inserted or added; (53αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 590; (53αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 589 have been deleted, substituted, inserted, or added; (53αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 589; or (53αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 589; (53αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 591 to 597; (53αA2) triosephosphate isomerase, cytosolic or a mutant thereof, which is any one of the following proteins (53αA2-a) to (53αA2-e): (53αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 599 in which one or several amino acids are deleted, substituted, inserted or added; (53αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 599; (53αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 598 have been deleted, substituted, inserted, or added; (53αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 598; or (53αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 598; or (53αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 600 to 604; (54α)(54αA1)superoxide dismutase [Fe], chloroplastic isoform X1 or The mutant is any one of the following proteins (54αA1-a) to (54αA1-e): (54αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 606 in which one or several amino acids are deleted, substituted, inserted or added; (54αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 606; (53αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 605 have been deleted, substituted, inserted, or added; (54αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 605; or (54αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 605; (54αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 607 to 611; (54αA2) iron-superoxide dismutase or a mutant thereof, Any of the proteins 2-a) to (54αA2-e): (54αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 613 in which one or several amino acids are deleted, substituted, inserted or added; (54αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 613; (54αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 612 have been deleted, substituted, inserted, or added; (54αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 612; or (54αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 612; or (54αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 614 to 616; or (55α)(55αA1) 51 kDa seed maturation protein precursor or a mutant thereof, which is any one of the following proteins (55αA1-a) to (55αA1-e): (55αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 618 in which one or several amino acids are deleted, substituted, inserted or added; (55αA1-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 618; (55αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 617 have been deleted, substituted, inserted, or added; (55αA1-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 617; or (55αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 617; (55αB1) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 619 to 635; (55αA2)Lea protein precursor or a mutant thereof, Any of the proteins a) to (55αA2-e): (55αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 637 in which one or several amino acids are deleted, substituted, inserted or added; (55αA2-b) a protein containing an amino acid sequence having 70% or more identity to the amino acid sequence set forth in SEQ ID NO: 637; (55αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 636 have been deleted, substituted, inserted, or added; (55αA2-d) a protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity to the nucleotide sequence set forth in SEQ ID NO: 636; or (55αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 636; or (55αB2) a protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 638 to 649; as an antigen.

[0019] [2] A diagnostic composition for soybean allergy, comprising at least one of the proteins identified as (1α) to (55α) in [1] above as an antigen.

[0020] [3] A method for providing an indicator for diagnosing soy allergy in a subject, comprising the steps of: (i) contacting a sample obtained from a subject with an antigen, wherein the sample contains Ig antibodies; is a solution; (ii) detecting binding of IgE antibodies to the antigen in a sample obtained from the subject; (iii) if binding of the subject's IgE antibodies to the antigen is detected, an indication that the subject is allergic to soy is provided; wherein the antigen is at least one of the proteins identified as (1α) to (55α) in [1] above.

[0021] [4] A pharmaceutical composition comprising at least one of the proteins identified as (1α) to (55α) in [1] above.

[0022] [5] The pharmaceutical composition according to [4] above for treating soybean allergy.

[0023] [6] Soybeans or soybean processed products characterized by having antigens removed or reduced, wherein the antigens are at least one of the proteins identified as (1α) to (55α) in [1] above.

[0024] [7] A method for producing a soybean processed product in which antigens have been removed or reduced, comprising a step of confirming that the antigens have been removed or reduced during the production process of the processed product, wherein the antigen is at least one of the proteins identified as (1α) to (55α) in [1] above.

[0025] [8] A tester for determining the presence or absence of a soybean antigen in a subject, characterized by comprising an antibody that binds to at least one of the proteins identified as (1α) to (55α) in [1] above.

[0026] [9] An antigen derived from soybean, which is at least one of the proteins identified as (1α) to (55α) in [1] above, and which causes allergy to soybean.

[0027] The present inventors also succeeded in finding an epitope for the novel antigen.

[0028] As described above, allergic reactions are induced by the interaction between an allergic patient's IgE antibody and a specific antigen. Here, the IgE antibody recognizes and binds to an epitope, which is a specific amino acid sequence in an allergen component. Because an epitope has a relatively short amino acid sequence, if the same amino acid sequence is present in different allergen components, the IgE antibody can bind to multiple allergen components. When different allergen components share a common epitope, resulting in the binding of an allergic patient's IgE antibody to both, the allergens exhibit cross-reactivity (also referred to as cross-antigenicity). Therefore, the epitope identified in the present application enables the diagnosis and treatment of allergies, including cross-reactivity, and the detection of multiple allergen components containing the epitope.

[0029] Based on this finding, the present invention has been completed. That is, in another aspect, the present invention may be as follows.

[0030]

[10] A polypeptide that specifically binds to IgE antibodies of an allergic patient, comprising: (1β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 650 to 660; (2β) at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 661 to 692 polypeptides containing strings; (4β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 717 to 731; (5β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 732 to 738; (6β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 739 and 740; (7β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 741 to 744; (9β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 745 to 749; (11β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 751 to 754; (12β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 755; (13β) a polypeptide comprising the amino acid sequence of SEQ ID NOs: 756 to 758; (14β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 759 to 764; (15β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 765 and 766; (17β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 767; (18β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 750, 768 to 775; (19β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 776 to 787; (25β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 814 and 815; (26β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 816 to 819; (27β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 820; (28β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 821 to 835; (29β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 836 to 839; (34β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 840 to 846; (35β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 847 to 856; (36β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 857 to 861; (38β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 862 to 892; (39β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 893 to 895; (40β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 896 to 902; (41β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 903; (42β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 904 to 906; (45β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 910 to 912; (46β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 913 to 915; (47β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 916 to 918; (48β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 919 to 922; (50β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 924 to 927; (51β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 928 to 930; (52β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 931 to 938; (53β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 939; (54β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 940 to 943; (55β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 944 to 952; The polypeptide, wherein the polypeptide is any one of the following:

[0031]

[11] A polypeptide that specifically binds to IgE antibodies of an allergic patient, comprising: (3β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 693 to 716; (20β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 788 to 792; (21β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 793 to 802; (22β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 803 to 808; (23β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 809 to 812; (24β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 813; (44β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 907 to 909; (49β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 923; (57β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 953 to 955; (58β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 956 to 960; (59β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 961 and 962; (60β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 963; The polypeptide, wherein the polypeptide is any one of the following:

[0032]

[12] The polypeptide according to

[10] or

[11] above, which has 500 or less amino acid residues.

[0033]

[13] A kit for diagnosing allergies, comprising at least one of the polypeptides described in any one of

[10] to

[12] above.

[0034]

[14] A composition for diagnosing allergies, comprising at least one of the polypeptides described in any one of

[10] to

[12] above as an antigen.

[0035]

[15] A method for providing an indicator for diagnosing allergies in a subject, comprising the steps of: (i) contacting a sample obtained from a subject with an antigen, wherein the sample is a solution containing Ig antibodies; (ii) detecting binding of IgE antibodies to the antigen in a sample obtained from the subject; (iii) if binding of the subject's IgE antibodies to the antigen is detected, an indication that the subject is allergic is provided; wherein the antigen is at least one of the polypeptides described in any one of

[10] to

[12] above.

[0036]

[16] A pharmaceutical composition comprising at least one of the polypeptides described in any one of

[10] to

[12] above.

[0037]

[17] The pharmaceutical composition according to

[16] above for treating allergies.

[0038]

[18] A tester for determining the presence or absence of an antigen in a subject, characterized by comprising an antibody that binds to at least one of the polypeptides described in any one of

[10] to

[12] above.

[0039]

[19] A food raw material or edible processed product characterized in that an antigen has been removed or reduced, or a polypeptide has been cleaved or removed, wherein the antigen is at least one of the polypeptides described in any one of

[10] to

[12] above.

[0040]

[20] A method for producing an edible processed product in which an antigen has been removed or reduced, or a polypeptide has been cleaved or removed, the method comprising a step of confirming that the antigen has been removed or reduced, or the polypeptide has been cleaved or removed, during the production process of the processed product, wherein the antigen is at least one of the polypeptides described in any one of

[10] to

[12] above. [Effects of the Invention]

[0041] The present invention provides a novel antigen for soybean allergy. Because the present invention identifies a novel antigen (allergen component) that causes soybean allergy, it can provide a highly sensitive method and kit for diagnosing soybean allergy, a pharmaceutical composition containing the antigen, and soybeans or soybean processed products in which the antigen has been removed or reduced.

[0042] Furthermore, the present invention provides a novel polypeptide containing an epitope of an allergen. By utilizing the polypeptide of the present invention, it is possible to provide a highly sensitive method and kit for diagnosing allergies, a pharmaceutical composition containing the polypeptide, and a food ingredient or edible processed product from which an antigen containing the polypeptide has been removed or reduced, or from which the polypeptide has been cleaved or removed, as well as a method for producing the edible processed product. [Brief explanation of the drawings]

[0043] [Figure 1] Figure 1 is a photograph of a gel showing the migration pattern of proteins contained in soybeans by two-dimensional electrophoresis. The band on the left side of the photograph is the molecular weight marker band. [Figure 2] FIG. 2 is a photograph of an immunoblot using serum from a healthy subject against two-dimensional electrophoresis patterns of proteins contained in soybeans. [Figure 3A]Figure 3A is a photograph of an immunoblot using the serum of soybean-allergic patient 1α against the two-dimensional electrophoresis pattern of proteins contained in soybean. The spots indicated by white lines or surrounded by squares indicate spots to which the serum of the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 3B] Figure 3B is a photograph of an immunoblot using the serum of soybean-allergic patient 2α against the two-dimensional electrophoresis pattern of proteins contained in soybean. The spots indicated by white lines or surrounded by squares indicate spots to which the serum of the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 3C] Figure 3C is a photograph of an immunoblot using serum from soybean-allergic patient 3α against a two-dimensional electrophoresis pattern of proteins contained in soybean. The spots indicated by white lines or surrounded by squares indicate spots to which the serum from the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 3D] Figure 3D is a photograph of an immunoblot using serum from a soybean-allergic patient 4α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. The spots indicated by white lines indicate spots to which the serum from the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 3E] Figure 3E is a photograph of an immunoblot using serum from a soybean-allergic patient 5α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. The spots indicated by white lines indicate spots to which the serum from the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 3F]Figure 3F is a photograph of an immunoblot using serum from soybean-allergic patient 6α against a two-dimensional electrophoresis pattern of proteins contained in soybean. The spots indicated by white lines or surrounded by squares indicate spots to which the serum from the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 3G] Figure 3G is a photograph of an immunoblot using serum from soybean-allergic patient 7α against the two-dimensional electrophoresis pattern of proteins contained in soybean. The squared spots indicate spots to which the serum from the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 3H] Figure 3H is a photograph of an immunoblot using serum from soybean-allergic patient 8α against a two-dimensional electrophoresis pattern of proteins contained in soybean. The spots indicated by white lines or surrounded by squares indicate spots to which the serum from the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 3I] Figure 3I is a photograph of an immunoblot using serum from a soybean-allergic patient 9α against a two-dimensional electrophoresis pattern of proteins contained in soybeans. The spots indicated by white lines or surrounded by squares indicate spots to which the serum from the soybean-allergic patient reacted specifically. The number (n) indicates the number of each spot, and each corresponds to the spot identified as "nα" in this specification. [Figure 4] FIG. 4 shows an example of the results obtained when a peptide having the minimum number of amino acids that functions as an epitope was determined by the overlapping method. [Figure 5] FIG. 5 shows an example of the results of examining positions important for antigenic expression in epitopes identified by the alanine scanning technique. [Figure 6]FIG. 6 is a graph showing the results of examining cross-reactivity. DETAILED DESCRIPTION OF THE INVENTION

[0044] The present invention will be specifically described below, but the present invention is not limited thereto.

[0045] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those skilled in the art.

[0046] When an amino acid sequence is shown in this specification, it is written using the single-letter code for amino acids that is well known to those skilled in the art, with the amino terminus at the left and the carboxy terminus at the right.

[0047] As used herein, allergy refers to an adverse hypersensitivity reaction that occurs when a living organism that has been sensitized to a certain antigen is reintroduced to that antigen. In many food allergic diseases, antigen-specific IgE antibodies are produced in the blood and tissues. The IgE antibodies bind to mast cells or basophils. When an antigen specific to the IgE antibodies re-enters the body of an allergic patient, the antigen combines with the IgE antibodies bound to mast cells or basophils, and the IgE antibodies cross-link on the cell surface, resulting in the physiological effects of IgE antibody-antigen interaction. These physiological effects include the release of histamine, serotonin, heparin, eosinophil chemotactic factor, and various leukotrienes. These released substances trigger allergic reactions caused by the combination of IgE antibodies and specific antigens. Allergic reactions caused by specific antigens manifest through the above pathway.

[0048] The allergies targeted by the present invention are not particularly limited as long as they are allergies to allergens containing the epitopes used, and may include allergies to plants of the families Malvaceae, Rubiaceae, Brassicaceae, Gramineae, Cucurbitaceae, Asteraceae, Veronicaceae, Juglandaceae, Rhamnaceae, Pedaliaceae, Apiaceae, Euphorbiaceae, Solanaceae, Bromeliaceae, Papayaceae, Rosaceae, Amaranthaceae, Vitaceae, Fabaceae, Lythraceae, and / or Birchaceae. Examples of plants in the Malvaceae family include mulukhiyah (scientific name: Corchorus olitorius) and cacao (scientific name: Theobroma cacao), and examples of plants in the Rubiaceae family include robusta coffee tree (scientific name: Coffea canephora), and examples of plants in the Brassicaceae family include bok choy (scientific name: Brassica rapa), radish (scientific name: Raphanus sativus), Examples of plants in the grass family include sorghum (scientific name: Sorghum bicolor), maize (scientific name: Zea mays), and bread wheat (scientific name: Triticum aestivum). Examples of plants in the Cucurbitaceae family include melon (scientific name: Cucumis melo), bitter melon (scientific name: Momordica charantia), and cucumber (scientific name: Cucumis sativus). Examples of plants in the Asteraceae family include sunflower (scientific name: Helianthus annuus). Examples of plants in the family Asparagaceae include asparagus (scientific name Asparagus officinalis). Examples of plants in the Juglandaceae family include the oak walnut (scientific name Juglans regia), and the black plum As a plant of the family Ziziphus, there is the jujube (scientific name Ziziphus jujuba), and as a plant of the family Pedaliaceae, there is the sesame. Examples of plants in the Apiaceae family include carrots (Daucus carota subsp. Sativus), etc. Examples of plants in the Euphorbiaceae family include cassava (Manihot esculenta), etc. Examples of plants in the Solanaceae family include chili peppers (Capsicum annuum) and tomatoes (Solanum lycopersicum), etc. Examples of plants in the Bromeliaceae family include cucumbers (Cucumber japonica), cucumbers (Cucumber japonica), and cucumbers (Cucumber japonica). Examples of plants in the Papaya family include the pineapple (scientific name: Ananas comosus), and examples of plants in the Papaya family include the papaya (scientific name: Carica papaya), and examples of plants in the Rosaceae family include the apple (scientific name: Malus Examples of plants in the Amaranthaceae family include quinoa (Chenopodium quinoa), spinach (Spinacia oleracea), and beet (Beta vulgaris subsp. vulgaris). Examples of plants in the Vitaceae family include European grape (Vitis vinifera). Leguminous plants include pigeon pea (Cajanus cajan), adzuki bean (Vigna angularis), wild soybean (Glycine soja), and soybean (Glycine max). Examples of plants in this family include the pomegranate (scientific name Punica granatum), which is considered to be a member of the birch family. Examples include birch (scientific name: Betula platyphylla). Allergies can cause allergic reactions when an antigen is contacted or ingested. Here, "contact" refers to touching an object, and in the case of the human body, it refers to adhesion to the skin, mucous membranes (eyes, lips, etc.). Furthermore, "ingestion" refers to taking something into the body, such as by inhalation or oral administration. Generally, an allergic reaction that occurs when food is ingested is specifically referred to as a food allergy. In a preferred embodiment, the allergy may be a food allergy.

[0049] As used herein, allergy to soybean refers to a state in which an allergic reaction occurs due to antigens such as proteins contained in soybeans.

[0050] As used herein, an antigen is a substance that induces an allergic reaction and is also referred to as an allergen component. Antigens are preferably proteins.

[0051] As used herein, a protein is a molecule having a structure in which natural amino acids are linked by peptide bonds. The number of amino acids contained in a protein is not particularly limited. As used herein, the term "polypeptide" also refers to a molecule having a structure in which natural amino acids are linked by peptide bonds. The number of amino acids contained in a polypeptide is not particularly limited. "Polypeptide" encompasses the concept of "protein." Furthermore, polypeptides in which approximately 2 to 50 amino acids are linked by peptide bonds are sometimes referred to as peptides. Furthermore, when optical isomers of amino acids are possible, the L-isomer is indicated unless otherwise specified. The notation method for the amino acid sequence of a protein, polypeptide, or peptide used herein is based on standard usage and the notation method commonly used in the art, and is represented by the single-letter notation of amino acids, with the left direction being the amino-terminal direction and the right direction being the carboxy-terminal direction. In the single-letter notation of an amino acid, X represents any substance having an amino group and a carboxyl group that can bond to the amino acids at both ends, and specifically represents any of the 20 natural amino acids.

[0052] Identification of antigens The antigens that cause soybean allergies were identified using the above method for proteins contained in soybeans. Specifically, soybean proteins were subjected to two-dimensional electrophoresis under the following conditions.

[0053] The first-dimension electrophoresis gel used was an isoelectric focusing gel with a gel length of 5-10 cm, a gel pH range of 3-10, and a pH gradient of the gel in the direction of migration, where the total length of the gel is 1, the gel length up to pH 5 is a, the gel length from pH 5 to 7 is b, and the gel length above pH 7 is c. Specifically, the gel used was an IPG gel Immobiline Drystrip (pH 3-10NL) manufactured by GE Healthcare Biosciences, Inc. (hereafter abbreviated as GE). The electrophoresis equipment used was an IPGphor manufactured by GE. The upper limit of the current value of the electrophoresis device was set to 75 μA per gel, and the voltage program was as follows: (1) a constant voltage step of 300 V up to 750 Vhr (the current change during the 30 minutes of electrophoresis before the end of this step was 5 μA), (2) the voltage was gradually increased to 1000 V over 300 Vhr, (3) the voltage was further increased gradually to 5000 V over 4500 Vhr, and (4) the first-dimension isoelectric focusing was then performed at a constant voltage of 5000 V until a total Vhr of 12000 was reached.

[0054] In the second dimension, the gel concentration at the base of the migration direction is set to 3-6%. SDS-PAGE was performed using a polyacrylamide gel in which the gel concentration at the end was set higher than that at the base end in the electrophoresis direction, specifically, using NuPAGE 4-12% Bris-Tris Gels IPG well mini 1mm manufactured by Life Technologies. The electrophoresis buffer used was 50 mM MOPS, 50 mM Tris base, 0.1% (w / v) SDS, 1 mM EDTA were used and electrophoresis was carried out at a constant voltage of 200 V for approximately 45 minutes.

[0055] As a result, when soybean proteins were subjected to two-dimensional electrophoresis under the above conditions, the following spots on the gel were found to specifically bind to IgE antibodies from patients with soybean allergies. Spot 1α: molecular weight 70-120 kDa, pI 2.5-6.5 Spot 2α: molecular weight 50-120 kDa, pI 2.5-6.5 Spot 4α: molecular weight 70-120 kDa, pI 3.5-7.5 Spot 5α: molecular weight 70-170 kDa, pI 3.5-7.5 Spot 6α: molecular weight 70-120 kDa, pI 3.5-7.5 Spot 7α: molecular weight 50-120 kDa, pI 3.5-7.5 Spot 8α: molecular weight 50-120 kDa, pI 3.5-8.5 Spot 9α: molecular weight 50-120 kDa, pI 3.5-8.5 Spot 10α: molecular weight 30-90 kDa, pI 3.5-7.5 Spot 11α: molecular weight 30-90 kDa, pI 3.5-8.5 Spot 12α: molecular weight 30-90 kDa, pI 3.5-8.5 Spot 13α: molecular weight 30-90 kDa, pI 3.5-7.5 Spot 14α: molecular weight 30-90 kDa, pI 2.5-6.5 Spots 15α and 16α: molecular weight 20-90 kDa, pI 3.5-7.5 Spot 17α: molecular weight 20-90 kDa, pI 3.5-7.5 Spot 18α: molecular weight 30-90 kDa, pI 3.5-8.5 Spot 19α: molecular weight 30-90 kDa, pI 3.5-8.5 Spot 25α: molecular weight 20-90 kDa, pI 3.5-7.5 Spot 26α: molecular weight 20-90 kDa, pI 3.5-7.5 Spot 27α: molecular weight 20-90 kDa, pI 3.5-7.5 Spot 28α: molecular weight 10-70 kDa, pI 3.5-7.5 Spots 29α, 30α, 31α, 32α, and 33α: molecular weight 10–70 kDa, pI 3.5–8.5 Spot 34α: molecular weight 10-70 kDa, pI 5.5-10.5 Spot 35α: molecular weight 20-90 kDa, pI 5.5-10.5 Spots 36α and 37α: molecular weight 10-70 kDa, pI 3.5-8.5 Spot 38α: molecular weight 70-170 kDa, pI 5.5-10.5 Spot 39α: molecular weight 5-60 kDa, pI 5.5-10.5 Spots 40α and 56α: molecular weight 5-60 kDa, pI 5.5-10.5 Spot 41α: molecular weight 5-60 kDa, pI 5.5-10.5 Spots 42α and 43α: molecular weight 5-60 kDa, pI 5.5-10.5 Spot 45α: molecular weight 2-50 kDa, pI 3.5-7.5 Spot 46α: molecular weight 2-50 kDa, pI 3.5-7.5 Spot 47α: molecular weight 5-50 kDa, pI 3.5-7.5 Spot 48α: molecular weight 2-50 kDa, pI 3.5-8.5 Spot 50α: molecular weight 2-50 kDa, pI 2.5-6.5 Spot 51α: molecular weight 5-60 kDa, pI 2.5-6.5 Spot 52α: molecular weight 10-70 kDa, pI 3.5-7.5 Spot 53α: molecular weight 5-60 kDa, pI 3.5-8.5 Spot 54α: molecular weight 5-60 kDa, pI 3.5-8.5 Spot 55α: molecular weight 30-90 kDa, pI 5.5-10.5

[0056] antigen (1α) Spot 1α antigen Spot 1α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 71 to 104 were detected.

[0057] Furthermore, when the mass data obtained from the mass spectrometer for spot 1α was analyzed by comparing it with NCBI protein data, endoplasmin homolog isoform X2 (amino acid sequence: SEQ ID NO: 70, nucleotide sequence encoding it: SEQ ID NO: 69) was identified as a protein containing any of SEQ ID NOs: 71 to 87, and endoplasmin homolog isoform X2 (amino acid sequence: SEQ ID NO: 89, nucleotide sequence encoding it: SEQ ID NO: 88) was identified as a protein containing any of SEQ ID NOs: 90 to 104.

[0058] Therefore, in the present application, the antigen of spot 1α may be any of the proteins selected from the group consisting of (1αA1-a) to (1αA1-e), (1αB1), (1αA2-a) to (1αA2-e), and (1αB2). (1αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 70 in which one or several amino acids have been deleted, substituted, inserted or added. (1αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 70, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical. (1αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 69 have been deleted, substituted, inserted or added. (1αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 69. (1αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 69. (1αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 71 to 87, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or all of said amino acid sequences. Here, the amino acid sequence represented by any of SEQ ID NOs: 71 to 87 may have one or several amino acids deleted, substituted, inserted, or added. (1αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 89 in which one or several amino acids have been deleted, substituted, inserted or added. (1αA2-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 89, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical. (1αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 88 have been deleted, substituted, inserted or added. (1αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 88. (1αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 88. (1αB2) At least one amino acid sequence selected from the group consisting of SEQ ID NOs: 90 to 104 A protein comprising one of the amino acid sequences, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of the amino acid sequences, wherein the amino acid sequence represented by any of SEQ ID NOs: 71 to 87 may have one or several amino acids deleted, substituted, inserted, or added.

[0059] The protein selected from the group consisting of (1αA1-a) to (1αA1-e), (1αB1), (1αA2-a) to (1αA2-e), and (1αB2) may be a protein that appears as a spot with a molecular weight of 70 to 120 kDa, preferably a molecular weight of around 80 to 110 kDa, and an isoelectric point of 2.5 to 6.5, preferably 3.0 to 6.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0060] Furthermore, the epitopes of the antigens (1αA1-a) to (1αA1-e) and (1αB1) are located at amino acids 546 to 553 (SEQ ID NO: 652), 653 to 661 (SEQ ID NO: 655), 781 to 795 (SEQ ID NO: 657), 252 to 266 (SEQ ID NO: 658), 771 to 785 (SEQ ID NO: 659), and 493 to 502 (SEQ ID NO: 660) of SEQ ID NO: 70. When the antigen of spot 1α contains a mutation in the amino acid sequence of SEQ ID NO: 70, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 70.

[0061] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 1α may be the following mutant.

[0062] Of the epitope having the sequence of SEQ ID NO: 652, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 650 or 651. Therefore, in another preferred embodiment, when the antigen of spot 1α contains a mutation in the amino acids of SEQ ID NO: 70, the antigen may be one in which amino acids 546 to 553 in SEQ ID NO: 70 have the amino acid sequence of SEQ ID NO: 650 or 651.

[0063] Of the epitope having the sequence of SEQ ID NO: 655, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 653 or 654. Therefore, in another preferred embodiment, when the antigen of spot 1α contains a mutation in the amino acid sequence of SEQ ID NO: 70, the antigen may be one in which amino acids 653 to 661 in SEQ ID NO: 70 are the amino acid sequence of SEQ ID NO: 653 or 654.

[0064] Of the epitope having the sequence of SEQ ID NO: 657, the site important for binding to IgE antibodies of allergy patients is the site represented by amino acids other than X in SEQ ID NO: 656. Therefore, in another preferred embodiment, when the antigen of spot 1α contains a mutation in the amino acid sequence of SEQ ID NO: 70, the antigen may be one in which amino acids 781 to 795 in SEQ ID NO: 70 are the amino acid sequence of SEQ ID NO: 656.

[0065] Preferably, the protein that is an antigen of spot 1α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 70 or 89 (endoplasmin homolog isoform X2), or causes allergy to soybean.

[0066] (2α) Spot 2α antigen Spot 2α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 107 to 153 were detected.

[0067] Furthermore, when the mass data obtained from the mass spectrometer for Spot 2α was analyzed by collating it with the protein data of NCBI, it was found that the protein containing any of SEQ ID NOS: 107 to 120 was heat shock cognate protein 80 (amino acid sequence: SEQ ID NOS: 106, base sequence encoding it: SEQ ID NOS: 105), As a protein containing any one of SEQ ID NOS: 123 to 137, heat shock protein 90-1 (amino acid sequence: SEQ ID NOS: 122, and a nucleic acid encoding it) The hypothetical protein GLYMA_02G302500 was identified as a protein containing either the base sequence represented by SEQ ID NO: 121 or any of SEQ ID NOs: 140 to 153.

[0068] Therefore, in the present application, the antigen of spot 1α may be any of the proteins selected from the group consisting of (2αA1-a) to (2αA1-e), (2αB1), (2αA2-a) to (2αA2-e), (2αB2), (2αA3-a) to (2αA3-e), and (2αB3). (2αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 106 in which one or several amino acids have been deleted, substituted, inserted or added. (2αA1-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 106, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical. (2αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 105 have been deleted, substituted, inserted or added. (2αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 105. (2αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 105. (2αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 107 to 120, preferably at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 107 to 120. (2αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 122 in which one or several amino acids have been deleted, substituted, inserted or added. (2αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 122. (2αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 121 have been deleted, substituted, inserted or added. (2αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 121. (2αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 121. (2αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 123 to 137, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 123 to 137. (2αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 139 in which one or several amino acids have been deleted, substituted, inserted or added. (2αA3-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 139. (2αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 138 have been deleted, substituted, inserted or added. (2αA3-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 138. (2αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 138. (2αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 140 to 153, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 140 to 153.

[0069] The protein selected from the group consisting of (2αA1-a) to (2αA1-e), (2αB1), (2αA2-a) to (2αA2-e), (2αB2), (2αA3-a) to (2αA3-e), and (2αB3) may be a protein that appears as a spot with a molecular weight of 50 to 120 kDa, preferably a molecular weight of around 60 to 110 kDa, and an isoelectric point of 2.5 to 6.5, preferably 3.0 to 6.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0070] Furthermore, the epitopes of the above (2αA1-a) to (2αA1-e) and (2αB1) antigens are amino acids 42 to 50 (SEQ ID NO: 663), amino acids 51 to 65 (SEQ ID NO: 666), amino acids 69 to 73 (SEQ ID NO: 669), amino acids 221 to 235 (SEQ ID NO: 670), amino acids 351 to 365 (SEQ ID NO: 671), amino acids 361 to 375 (SEQ ID NO: 672), and amino acids 411 to 425 (SEQ ID NO: 675) of SEQ ID NO: 106. , amino acids 551 to 565 (SEQ ID NO: 676), amino acids 671 to 685 (SEQ ID NO: 677), amino acids 681 to 695 (SEQ ID NO: 678), amino acids 41 to 55 (SEQ ID NO: 681), amino acids 451 to 465 (SEQ ID NO: 684), amino acids 271 to 285 (SEQ ID NO: 689), amino acids 51 to 59 (SEQ ID NO: 690), amino acids 65 to 72 (SEQ ID NO: 691), and amino acids 453 to 460 (SEQ ID NO: 692). When the antigen of spot 2α contains a mutation in the amino acid sequence of SEQ ID NO: 106, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 106.

[0071] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 2α may be the following mutant.

[0072] Of the epitope having the sequence of SEQ ID NO: 663, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 661 or 662. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation in the amino acid sequence of SEQ ID NO: 106, the antigen may be one in which amino acids 42 to 50 in SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 661 or 662.

[0073] Among the epitopes having the sequence of SEQ ID NO: 666, those that bind to IgE antibodies of allergy patients In this case, what is important is the site represented by an amino acid other than X in SEQ ID NO: 664 or 665. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation with respect to the amino acid sequence of SEQ ID NO: 106, the antigen may be one in which amino acids 51 to 65 in SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 664 or 665.

[0074] Of the epitope having the sequence of SEQ ID NO: 669, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 667 or 668. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation in the amino acid sequence of SEQ ID NO: 106, the antigen may be one in which amino acids 69 to 73 in SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 667 or 668.

[0075] Of the epitope having the sequence of SEQ ID NO: 675, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 673 or 674. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation in the amino acid sequence of SEQ ID NO: 106, the antigen may be one in which amino acids 411 to 425 in SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 673 or 674.

[0076] Of the epitope having the sequence of SEQ ID NO: 681, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 679 or 680. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation in the amino acid sequence of SEQ ID NO: 106, the antigen may be one in which amino acids 41 to 55 in SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 679 or 680.

[0077] Of the epitope having the sequence of SEQ ID NO: 684, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 682 or 685. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation in the amino acid sequence of SEQ ID NO: 106, the antigen may be one in which amino acids 451 to 465 in SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 682 or 685.

[0078] Of the epitope having the sequence of SEQ ID NO: 689, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 688. Therefore, in another preferred embodiment, when the antigen of spot 2α contains a mutation in the amino acid sequence of SEQ ID NO: 106, the antigen may be one in which amino acids 271 to 285 in SEQ ID NO: 106 are the amino acid sequence of SEQ ID NO: 688.

[0079] Preferably, the protein that is the antigen of spot 2α is a protein having the amino acid sequence of SEQ ID NO: 106 (heat shock cognate protein 80), a protein having the amino acid sequence of SEQ ID NO: 122, Protein having the sequence (heat shock protein 90-1) or amino acid sequence of SEQ ID NO: 139 It has activity equivalent to that of the hypothetical protein GLYMA_02G302500, or causes soy allergies.

[0080] (4α) Spot 4α antigen As a result of performing sequence identification by mass spectrometry for spot 4α, the amino acid sequences of SEQ ID NOs: 156 and 157 were detected.

[0081] Furthermore, when the mass data obtained from the mass spectrometer for spot 4α was analyzed by collating it with the protein data of NCBI, it was identified as embryo-specific urease isoform X1 (amino acid sequence: SEQ ID NO: 155, base sequence encoding it) as a protein containing either SEQ ID NO: 156 or 157. :SEQ ID NO: 154), was identified.

[0082] Therefore, in the present application, the antigen of spot 4α may be any protein selected from the group consisting of (4αA-a) to (4αA-e) and (4αB) below. (4αA-a) A protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted or added in SEQ ID NO: 155. (4αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 155. (4αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 154 have been deleted, substituted, inserted or added. (4αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 154. (4αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 154. (4αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 156 and 157, preferably a protein comprising both of said amino acid sequences, wherein the amino acid sequence represented by either SEQ ID NO: 156 or 157 may have one or several amino acids deleted, substituted, inserted or added.

[0083] The protein selected from the group consisting of (4αA-a) to (4αA-e) and (4αB) above may be a protein that appears as a spot with a molecular weight of 70 to 120 kDa, preferably a molecular weight of around 80 to 110 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0084] The epitope of the antigen of spot 4α is located at amino acids 121 to 130 (SEQ ID NO: 719), 289 to 295 (SEQ ID NO: 722), 293 to 302 (SEQ ID NO: 725), 501 to 515 (SEQ ID NO: 726), 571 to 585 (SEQ ID NO: 727), 591 to 605 (SEQ ID NO: 728), and 771 to 785 (SEQ ID NO: 731) of SEQ ID NO: 155. The antigen of spot 4α may retain the sequence of SEQ ID NO: 155 for amino acids at positions corresponding to at least one region of the epitope.

[0085] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 4α may be the following mutant.

[0086] Of the epitope having the sequence of SEQ ID NO: 719, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 717 or 718. Therefore, in another preferred embodiment, the antigen of spot 4α may be one in which amino acids 121 to 130 in SEQ ID NO: 155 are the amino acid sequence of SEQ ID NO: 717 or 718.

[0087] Among the epitopes having the sequence of SEQ ID NO: 722, those that bind to IgE antibodies of allergic patients In this case, what is important is the site represented by an amino acid other than X in SEQ ID NO: 720 or 721. Therefore, in another preferred embodiment, the antigen of spot 4α may be one in which amino acids 289 to 295 in SEQ ID NO: 155 are the amino acid sequence of SEQ ID NO: 720 or 721.

[0088] Of the epitope having the sequence of SEQ ID NO: 725, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 723 or 724. Therefore, in another preferred embodiment, the antigen of spot 4α may be one in which amino acids 293 to 302 in SEQ ID NO: 155 are the amino acid sequence of SEQ ID NO: 723 or 724.

[0089] Of the epitope having the sequence of SEQ ID NO: 731, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 729 or 730. Therefore, in another preferred embodiment, the antigen of spot 4α may be one in which amino acids 771 to 785 in SEQ ID NO: 155 are the amino acid sequence of SEQ ID NO: 729 or 730.

[0090] Preferably, the protein that is an antigen of spot 4α has an activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 155 (embryo-specific urease isoform X1), or causes soy allergies.

[0091] (5α) Spot 5α antigen As a result of performing sequence identification by mass spectrometry for spot 5α, the amino acid sequences of SEQ ID NOs: 160 and 161 were detected.

[0092] In addition, when the mass data obtained from a mass spectrometer for spot 5α was analyzed by comparing it with NCBI protein data, a protein containing either sequence number 160 or 161 was identified as alpha-1,4 glucan phosphorylase L isozyme, chloroplastic / amyloplastic (amino acid sequence: sequence number 159, base sequence encoding it: sequence number 158).

[0093] Therefore, in the present application, the antigen of spot 5α may be any protein selected from the group consisting of the following (5αA-a) to (5αA-e) and (5αB): (5αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 159 in which one or several amino acids have been deleted, substituted, inserted or added. (5αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 159. (5αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 158 have been deleted, substituted, inserted or added. (5αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 158. (5αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 158. (5αB) A protein comprising at least one of the amino acid sequences selected from the group consisting of SEQ ID NOs: 160 and 161, preferably a protein comprising both of said amino acid sequences. In this case, the amino acid sequence represented by either SEQ ID NO: 160 or 161 is one or several Amino acids may be deleted, substituted, inserted or added.

[0094] The protein selected from the group consisting of (5αA-a) to (5αA-e) and (5αB) above may be a protein that appears as a spot with a molecular weight of 70 to 170 kDa, preferably a molecular weight of around 80 to 160 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0095] The epitope of the antigen of spot 5α is located at amino acids 861 to 875 (SEQ ID NO: 734), 871 to 885 (SEQ ID NO: 735), 891 to 905 (SEQ ID NO: 736), 901 to 915 (SEQ ID NO: 737), and 951 to 965 (SEQ ID NO: 738) of SEQ ID NO: 159. The antigen of spot 5α may retain the sequence of SEQ ID NO: 159 for amino acids at positions corresponding to at least one region of the epitope.

[0096] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 5α may be the following mutant.

[0097] Of the epitope having the sequence of SEQ ID NO: 734, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 732 or 733. Therefore, in another preferred embodiment, the antigen of spot 5α may be one in which amino acids 861 to 875 in SEQ ID NO: 159 are the amino acid sequence of SEQ ID NO: 732 or 733.

[0098] Preferably, the protein that is an antigen of spot 5α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 159 (alpha-1,4 glucan phosphorylase L isozyme, chloroplastic / amyloplastic) or causes allergy to soybeans.

[0099] (6α) Spot 6α antigen Spot 6α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 164 to 172 were detected.

[0100] Furthermore, when the mass data obtained from the mass spectrometer for spot 6α was analyzed by collating it with the protein data of NCBI, aconitate hydratase 1 (amino acid sequence: Aconitate hydratase 1 (amino acid sequence: SEQ ID NO: 169, base sequence encoding it: SEQ ID NO: 168) was identified as a protein containing either SEQ ID NO: 163, base sequence encoding it: SEQ ID NO: 162, or any of SEQ ID NOs: 170 to 172.

[0101] Therefore, in the present application, the antigen of spot 6α may be any of the proteins selected from the group consisting of (6αA1-a) to (6αA1-e), (6αB1), (6αA2-a) to (6αA2-e), and (6αB2). (6αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 163 in which one or several amino acids have been deleted, substituted, inserted or added. (6αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 163. (6αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 162 have been deleted, substituted, inserted or added. (6αA1-d) 70% or more identity with the base sequence shown in SEQ ID NO: 162, preferably A protein containing an amino acid sequence that is encoded by 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more of a base sequence. (6αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 162. (6αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 164 to 167, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 164 to 167. (6αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 169 in which one or several amino acids have been deleted, substituted, inserted or added. (6αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 169. (6αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 168 have been deleted, substituted, inserted or added. (6αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 168. (6αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 168. (6αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 170 to 172, preferably at least two or all of the amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted or added in the amino acid sequence represented by any of SEQ ID NOs: 170 to 172.

[0102] The protein selected from the group consisting of (6αA1-a) to (6αA1-e), (6αB1), (6αA2-a) to (6αA2-e), and (6αB2) may be a protein that appears as a spot with a molecular weight of 70 to 120 kDa, preferably a molecular weight of around 80 to 110 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0103] Furthermore, the epitopes of the antigens (6αA1-a) to (6αA1-e) and (6αB1) are located at amino acids 761 to 775 (SEQ ID NO: 739) and 831 to 845 (SEQ ID NO: 740) of SEQ ID NO: 163. When the antigen of spot 6α contains a mutation in the amino acid sequence of SEQ ID NO: 163, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 163.

[0104] Preferably, the protein that is an antigen of spot 6α has an activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 163 or 169 (aconitate hydratase 1), or causes soy allergies.

[0105] (7α) Spot 7α antigen Spot 7α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 175 to 187 were detected.

[0106] In addition, for spot 7α, the mass data obtained from the mass spectrometer was submitted to the NCBI Tandem As a result of analysis in comparison with protein data, methionine synthase (amino acid sequence: SEQ ID NO: 175 to 187) was identified as a protein containing any one of SEQ ID NO: 175 to 187. 174, and the base sequence encoding it: SEQ ID NO: 173) was identified.

[0107] Therefore, in the present application, the antigen of spot 7α may be any protein selected from the group consisting of (7αA-a) to (7αA-e) and (7αB) below. (7αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 174 in which one or several amino acids have been deleted, substituted, inserted or added. (7αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 174. (7αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 173 have been deleted, substituted, inserted or added. (7αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 173. (7αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 173. (7αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 175 to 187, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 175 to 187.

[0108] The protein selected from the group consisting of (7αA-a) to (7αA-e) and (7αB) above may be a protein that appears as a spot with a molecular weight of 50 to 120 kDa, preferably a molecular weight of around 60 to 110 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0109] The epitope of the antigen of spot 7α is located at amino acids 471 to 485 (SEQ ID NO: 741) and amino acids 581 to 595 (SEQ ID NO: 744) of SEQ ID NO: 174. The antigen of spot 7α may retain the sequence of SEQ ID NO: 174 for amino acids at positions corresponding to at least one region of the epitope.

[0110] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 7α may be the following mutant.

[0111] Of the epitope having the sequence of SEQ ID NO: 744, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 742 or 743. Therefore, in another preferred embodiment, the antigen of spot 7α may be one in which amino acids 581 to 595 in SEQ ID NO: 174 are the amino acid sequence of SEQ ID NO: 742 or 743.

[0112] Preferably, the protein that is the antigen of spot 7α has an activity equivalent to that of the protein (methionine synthase) having the amino acid sequence of SEQ ID NO: 174, or ... It can cause allergies.

[0113] (8α) Spot 8α antigen Spot 8α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 190 to 199 were detected.

[0114] In addition, when the mass data obtained from the mass spectrometer for spot 8α was analyzed by comparing it with NCBI protein data, transketolase, chloroplastic (amino acid sequence: SEQ ID NO: 189, base sequence encoding it: SEQ ID NO: 188) was identified as a protein containing any of SEQ ID NOs: 190 to 199.

[0115] Therefore, in the present application, the antigen of spot 8α may be any protein selected from the group consisting of the following (8αA-a) to (8αA-e) and (8αB): (8αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 189 in which one or several amino acids have been deleted, substituted, inserted or added. (8αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 189. (8αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 188 have been deleted, substituted, inserted or added. (8αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 188. (8αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 188. (8αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 190 to 199, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 190 to 199.

[0116] The protein selected from the group consisting of (8αA-a) to (8αA-e) and (8αB) above may be a protein that appears as a spot with a molecular weight of 50 to 120 kDa, preferably a molecular weight of around 60 to 110 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0117] Preferably, the protein that is an antigen of spot 8α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 189 (transketolase, chloroplastic), or causes allergy to soybean.

[0118] (9α) Spot 9α antigen As a result of performing sequence identification by mass spectrometry for spot 9α, the amino acid sequence of SEQ ID NO: 202 was detected.

[0119] Furthermore, analysis of the mass data obtained from the mass spectrometer for spot 9α by collating it with the protein data of NCBI revealed that the protein containing SEQ ID NO: 202 was lysine-tRNA ligase, cytoplasmic-like isoform X2 (amino acid sequence: SEQ ID NO: 201, which is encoded by the The corresponding base sequence (SEQ ID NO: 200) was identified.

[0120] Therefore, in the present application, the antigen of spot 9α may be any protein selected from the group consisting of the following (9αA-a) to (9αA-e) and (9αB): (9αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 201 in which one or several amino acids have been deleted, substituted, inserted or added. (9αA-b) A protein containing an amino acid sequence that is 70% or more identical to the amino acid sequence shown in SEQ ID NO: 201, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical. (9αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 200 have been deleted, substituted, inserted or added. (9αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 200. (9αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 200. (9αB) A protein comprising the amino acid sequence shown in SEQ ID NO: 202. In this case, the amino acid sequence shown in SEQ ID NO: 202 may have one or several amino acids deleted, substituted, inserted or added.

[0121] The protein selected from the group consisting of (9αA-a) to (9αA-e) and (9αB) above may be a protein that appears as a spot with a molecular weight of 50 to 120 kDa, preferably a molecular weight of around 60 to 110 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0122] The epitope of the antigen of spot 9α is located at amino acids 236 to 245 (SEQ ID NO: 747) and amino acids 283 to 290 (SEQ ID NO: 749) of SEQ ID NO: 201. The antigen of spot 9α may retain the sequence of SEQ ID NO: 201 for amino acids at positions corresponding to at least one region of the epitope.

[0123] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 9α may be the following mutant.

[0124] Of the epitope having the sequence of SEQ ID NO: 747, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 745 or 746. Therefore, in another preferred embodiment, the antigen of spot 9α may be one in which amino acids 236 to 245 in SEQ ID NO: 201 are the amino acid sequence of SEQ ID NO: 745 or 746.

[0125] Of the epitope having the sequence of SEQ ID NO: 749, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 748. Therefore, in another preferred embodiment, the antigen of spot 9α may be one in which amino acids 283 to 290 in SEQ ID NO: 201 have the amino acid sequence of SEQ ID NO: 748.

[0126] Preferably, the protein that is an antigen of spot 9α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 201 (lysine-tRNA ligase, cytoplasmic-like isoform X2). It may have side effects or cause allergies to soy.

[0127] (10α) Spot 10α antigen As a result of performing sequence identification by mass spectrometry for spot 10α, SEQ ID NOs: 205 to 23 The amino acid sequence of 1 was detected.

[0128] Furthermore, analysis of the mass data obtained from the mass spectrometer for spot 10α by collating it with the protein data of NCBI revealed that the proteins containing any of SEQ ID NOS: 205 to 218 are chaperonin CPN60-2, mitochondrial (amino acid sequence: SEQ ID NOS: 204, nucleotide sequence encoding same: SEQ ID NOS: 203), and the proteins containing any of SEQ ID NOS: 221 to 231 are chaperonin CPN60-2, mitochondrial (amino acid sequence: SEQ ID NOS: 204, nucleotide sequence encoding same: SEQ ID NOS: 203). Mitochondrial-like isoform X1 (chaperonin CPN60-2, mitochondrial-like isoform X1) (amino acid sequence: SEQ ID NO: 220, base sequence encoding it: SEQ ID NO: No. 219) was identified.

[0129] Therefore, in the present application, the antigen of spot 10α may be any protein selected from the group consisting of (10αA1-a) to (10αA1-e), (10αB1), (10αA2-a) to (10αA2-e), and (10αB2). (10αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 204 in which one or several amino acids have been deleted, substituted, inserted or added. (10αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 204. (10αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 203 have been deleted, substituted, inserted or added. (10αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 203. (10αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 203. (10αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 205 to 218, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 205 to 218. (10αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 220 in which one or several amino acids have been deleted, substituted, inserted or added. (10αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 220. (10αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 219 have been deleted, substituted, inserted or added. (10αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 219. (10αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 219. (10αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 221 to 231, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of said amino acid sequences. In this regard, the amino acid sequence represented by any of SEQ ID NOs: 221 to 231 may have one or several amino acids deleted, substituted, inserted, or added.

[0130] The protein selected from the group consisting of (10αA1-a) to (10αA1-e), (10αB1), (10αA2-a) to (10αA2-e), and (10αB2) may be a protein that appears as a spot with a molecular weight of 30 to 90 kDa, preferably a molecular weight of around 40 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0131] Preferably, the protein that is an antigen of spot 10α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 204 (haperonin CPN60-2, mitochondrial) or a protein having the amino acid sequence of SEQ ID NO: 220 (chaperonin CPN60-2, mitochondrial-like isoform X1), or causes soy allergy.

[0132] (11α) Spot 11α antigen Spot 11α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 234 to 237 were detected.

[0133] Furthermore, when the mass data obtained from the mass spectrometer for spot 11α was analyzed by comparing it with the protein data from NCBI, polyadenylate-binding protein 8 isoform X3 (amino acid sequence: SEQ ID NO: 233, base sequence encoding it: SEQ ID NO: 232) was identified as a protein containing any of SEQ ID NOs: 234 to 237.

[0134] Therefore, in the present application, the antigen of spot 11α may be any protein selected from the group consisting of the following (11αA-a) to (11αA-e) and (11αB): (11αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 233 in which one or more amino acids have been deleted, substituted, inserted or added. (11αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 233. (11αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 232 have been deleted, substituted, inserted or added. (11αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 232. (11αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 232. (11αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 234 to 237, preferably a protein comprising at least two, three, or all of the amino acid sequences, wherein the amino acid sequence represented by any of SEQ ID NOs: 234 to 237 may have one or several amino acids deleted, substituted, inserted, or added.

[0135] The protein selected from the group consisting of (11αA-a) to (11αA-e) and (11αB) above may be a protein that appears as a spot with a molecular weight of 30 to 90 kDa, preferably a molecular weight of around 40 to 80 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0136] The epitope of the antigen of spot 11α is located at amino acids 454 to 463 (SEQ ID NO: 753) and amino acids 363 to 370 (SEQ ID NO: 754) of SEQ ID NO: 233. The antigen of spot 11α may retain the sequence of SEQ ID NO: 233 for amino acids at positions corresponding to at least one region of the epitope.

[0137] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 11α may be the following mutant.

[0138] Of the epitope having the sequence of SEQ ID NO: 753, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 751 or 752. Therefore, in another preferred embodiment, the antigen of spot 11α may be one in which amino acids 454 to 463 in SEQ ID NO: 223 have the amino acid sequence of SEQ ID NO: 751 or 752.

[0139] Preferably, the protein that is an antigen of spot 11α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 233 (polyadenylate-binding protein 8 isoform X3), or causes allergy to soybean.

[0140] (12α) Spot 12α antigen As a result of performing sequence identification by mass spectrometry for spot 12α, the amino acid sequence of SEQ ID NO: 240 was detected.

[0141] Furthermore, when the mass data obtained from the mass spectrometer for spot 12α was analyzed by collating it with the protein data of NCBI, it was identified as a protein containing SEQ ID NO: 240, namely, pyrophosphate-fructose 6-phosphate 1-phosphorotransferase subunit alpha-like (amino acid sequence: SEQ ID NO: 239, base sequence encoding it: SEQ ID NO: 240). Column number 238), was identified.

[0142] Therefore, in the present application, the antigen of spot 12α may be any protein selected from the group consisting of (12αA-a) to (12αA-e) and (12αB) below. (12αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 239 in which one or more amino acids have been deleted, substituted, inserted or added. (12αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 239. (12αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 238 have been deleted, substituted, inserted or added. (12αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 238. (12αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 238. (12αB) A protein comprising the amino acid sequence shown in SEQ ID NO: 240. In this case, the amino acid sequence shown in SEQ ID NO: 240 may have one or several amino acids deleted, substituted, inserted or added.

[0143] The protein selected from the group consisting of (12αA-a) to (12αA-e) and (12αB) above may be a protein that appears as a spot with a molecular weight of 30 to 90 kDa, preferably a molecular weight of around 40 to 80 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0144] The epitope of the antigen in spot 12α is located at amino acids 551 to 565 (SEQ ID NO: 755) of SEQ ID NO: 239. The antigen in spot 11α may retain the sequence of SEQ ID NO: 239 for the amino acids at positions corresponding to the epitope region.

[0145] Preferably, the protein that is the antigen of spot 12α has activity equivalent to the protein having the amino acid sequence of SEQ ID NO: 239 (pyrophosphate-fructose 6-phosphate 1-phosphotransferase subunit alpha-like), or is a protein that is the cause of soybean allergy. do.

[0146] (13α) Spot 13α antigen As a result of performing sequence identification by mass spectrometry for spot 13α, the amino acid sequences of SEQ ID NOs: 243 to 278 were detected.

[0147] Furthermore, when the mass data obtained from the mass spectrometer for spot 13α was analyzed by collating it with the protein data of NCBI, it was identified as a protein disulfide isomerase-like protein precursor (amino acid sequence: SEQ ID NO: 242, base sequence encoding it: SEQ ID NO: 241) as a protein containing any of SEQ ID NOs: 243 to 252, and a protein disulfide-isomerase (amino acid sequence: SEQ ID NO: 254, base sequence encoding it: SEQ ID NO: 255 to 278) as a protein containing any of SEQ ID NOs: 255 to 278. 3) was identified.

[0148] Therefore, in the present application, the antigen of spot 13α may be any of the proteins selected from the group consisting of (13αA1-a) to (13αA1-e), (13αB1), (13αA2-a) to (13αA2-e), and (13αB2). (13αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 242 in which one or several amino acids have been deleted, substituted, inserted or added. (13αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 242. (13αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 241 have been deleted, substituted, inserted or added. (13αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 241. (13αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 241. (13αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 243 to 252, preferably at least 2, 3, 4, 5, 6, 7, 8, 9, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 205 to 218. (13αA2-a) SEQ ID NO: 254 in which one or several amino acids are deleted, substituted, inserted or is a protein containing an added amino acid sequence. (13αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 254. (13αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 253 have been deleted, substituted, inserted or added. (13αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 253. (13αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 253. (13αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 255 to 278, preferably at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or all of said amino acid sequences. Here, the amino acid sequence shown in any of SEQ ID NOs: 221 to 231 may have one or more amino acids deleted, substituted, inserted, or added.

[0149] The protein selected from the group consisting of (13αA1-a) to (13αA1-e), (13αB1), (13αA2-a) to (13αA2-e), and (13αB2) may be a protein that appears as a spot with a molecular weight of 30 to 90 kDa, preferably a molecular weight of around 40 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0150] Furthermore, the epitopes of the antigens (13αA1-a) to (13αA1-e) and (13αB1) are located at amino acids 471 to 485 (SEQ ID NO: 758) of SEQ ID NO: 242. When the antigen of spot 13α contains a mutation in the amino acid sequence of SEQ ID NO: 242, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 242.

[0151] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 13α may be the following mutant.

[0152] Of the epitope having the sequence of SEQ ID NO: 758, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 756 or 757. Therefore, in another preferred embodiment, when the antigen of spot 13α contains a mutation in the amino acid sequence of SEQ ID NO: 242, the antigen may be one in which amino acids 471 to 485 in SEQ ID NO: 242 are the amino acid sequence of SEQ ID NO: 756 or 757.

[0153] Preferably, the protein that is the antigen of spot 13α is a protein having the amino acid sequence of SEQ ID NO: 242 (protein disulfide isomerase-like protein precursor) or a protein having the amino acid sequence of SEQ ID NO: 254 (protein disulfide isomerase). It has the same activity as or causes allergies to soy.

[0154] (14α) Spot 14α antigen Spot 14α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 281 to 289 were detected.

[0155] Furthermore, when the mass data obtained from the mass spectrometer for spot 14α was analyzed by comparing it with NCBI protein data, V-type proton ATPase subunit B2 (amino acid sequence: SEQ ID NO: 280, nucleotide sequence encoding it: SEQ ID NO: 279) was identified as a protein containing any of SEQ ID NOs: 281 to 284, and V-type proton ATPase subunit B2 (amino acid sequence: SEQ ID NO: 286, nucleotide sequence encoding it: SEQ ID NO: 285) was identified as a protein containing any of SEQ ID NOs: 287 to 289.

[0156] Therefore, in the present application, the antigen of spot 14α may be any of the proteins selected from the group consisting of (14αA1-a) to (14αA1-e), (14αB1), (14αA2-a) to (14αA2-e), and (14αB2). (14αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 280 in which one or several amino acids have been deleted, substituted, inserted or added. (14αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 280. (14αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 279 have been deleted, substituted, inserted or added. (14αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 279. (14αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 279. (14αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 281 to 284, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 281 to 284. (14αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 286 in which one or several amino acids have been deleted, substituted, inserted or added. (14αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 286. (14αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 285 have been deleted, substituted, inserted or added. (14αA2-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 285. (14αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 285. (14αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 287 to 289, preferably at least two or all of the amino acid sequences, wherein the amino acid sequence represented by any of SEQ ID NOs: 287 to 289 may have one or more amino acids deleted, substituted, inserted, or added.

[0157] Above (14αA1-a)~(14αA1-e), (14αB1), (14αA2-a) The protein selected from the group consisting of (14αA2-e), (14αA2-e), and (14αB2) may be a protein that appears as a spot with a molecular weight of 30 to 90 kDa, preferably a molecular weight of around 40 to 80 kDa, and an isoelectric point of 2.5 to 6.5, preferably 3.0 to 6.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section ``Identification of antigen.''

[0158] Furthermore, the epitopes of the antigens (14αA1-a) to (14αA1-e) and (14αB1) are located at amino acids 191 to 205 (SEQ ID NO: 761) and 391 to 405 (SEQ ID NO: 764) of SEQ ID NO: 280. When the antigen of spot 14α contains a mutation in the amino acid sequence of SEQ ID NO: 280, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 280.

[0159] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 14α may be the following mutant.

[0160] Of the epitope having the sequence of SEQ ID NO: 761, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 759 or 760. Therefore, in another preferred embodiment, when the antigen of spot 14α contains a mutation in the amino acid sequence of SEQ ID NO: 280, the antigen may be one in which amino acids 191 to 205 in SEQ ID NO: 280 each independently represent the amino acid sequence of SEQ ID NO: 759 or 760.

[0161] Of the epitope having the sequence of SEQ ID NO: 764, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 762 or 763. Therefore, in another preferred embodiment, when the antigen of spot 14α contains a mutation in the amino acid sequence of SEQ ID NO: 280, the antigen may be one in which amino acids 391 to 405 in SEQ ID NO: 280 each independently represent the amino acid sequence of SEQ ID NO: 762 or 763.

[0162] Preferably, the protein that is an antigen of spot 14α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 280 or 286 (V-type proton ATPase subunit B2), or causes allergy to soybean.

[0163] (15α, 16α) Spot 15α, 16α antigens As a result of performing sequence identification by mass spectrometry for spots 15α and 16α, the amino acid sequences of SEQ ID NOs: 292 to 318 were detected.

[0164] Furthermore, for spots 15α and 16α, the mass data obtained from the mass spectrometer was analyzed by collating it with the protein data of NCBI. As a result, UTP-glucose-1-phosphate uridylyltransferase (amino acid sequence: SEQ ID NO: 2) was identified as a protein containing any one of SEQ ID NOs: 292 to 304. 91, the base sequence encoding it: SEQ ID NO: 290), and hypothetical protein GLYMA_02G241100 (amino acid sequence: SEQ ID NO: 306, the base sequence encoding it) as a protein containing any of SEQ ID NOs: 307 to 318. Sequence number: SEQ ID NO: 305) was identified.

[0165] Therefore, in the present application, the antigens of spots 15α and 16α are selected from the group consisting of (15,16αA1-a) to (15,16αA1-e), (15,16αB1), (15,16αA2-a) to (15,16αA2-e), and (15,16αB2). The protein may be either (15,16αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 291 in which one or several amino acids have been deleted, substituted, inserted or added. (15,16αA1-b) A protein comprising an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 291. (15,16αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 290 have been deleted, substituted, inserted or added. (15,16αA1-d) A protein comprising an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 290. (15,16αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 290. (15,16αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 292 to 304, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 292 to 304. (15,16αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 306 in which one or several amino acids have been deleted, substituted, inserted or added. (15,16αA2-b) A protein containing an amino acid sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence shown in SEQ ID NO: 306. (15.16αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 305 have been deleted, substituted, inserted or added. (15,16αA2-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identity to the nucleotide sequence shown in SEQ ID NO: 305. (15,16αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 305. (15,16αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 307 to 318, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 307 to 318.

[0166] The protein selected from the group consisting of (15,16αA1-a) to (15,16αA1-e), (15,16αB1), (15,16αA2-a) to (15,16αA2-e), and (15,16αB2) may be a protein that appears as a spot with a molecular weight of 20 to 90 kDa, preferably around 30 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section ``Identification of antigen.''

[0167] Furthermore, the epitopes of the antigens (15,16αA1-a) to (15,16αA1-e) and (15,16αB1) are located at amino acids 211 to 225 (SEQ ID NO: 766) of SEQ ID NO: 291. When the antigens of spots 15α and 16α contain mutations in the amino acid sequence of SEQ ID NO: 291, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 291.

[0168] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigens of spots 15α and 16α may be the following mutants.

[0169] Of the epitope having the sequence of SEQ ID NO: 766, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 765. Therefore, in another preferred embodiment, when the antigen in spots 15α and 16α contains a mutation in the amino acid sequence of SEQ ID NO: 291, the antigen may be one in which amino acids 211 to 225 in SEQ ID NO: 291 are the amino acid sequence of SEQ ID NO: 765.

[0170] Preferably, the protein that is the antigen of spots 15α and 16α is a protein having the amino acid sequence of SEQ ID NO: 291 (UTP-glucose-1-phosphate uridylyltransferase) or or has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 306 (hypothetical protein GLYMA_02G241100), or causes allergy to soy.

[0171] (17α) Spot 17α antigen Spot 17α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 321 to 332 were detected.

[0172] Furthermore, when the mass data obtained from the mass spectrometer for spot 17α was analyzed by collating it with the protein data of NCBI, it was identified as a protein containing any one of SEQ ID NOS: 321 to 325, which is guanosine nucleotide diphosphate dissociation inhibitor 2 (amino acid sequence: As a protein containing any one of SEQ ID NO: 320, a base sequence encoding it: SEQ ID NO: 319, and SEQ ID NOs: 328 to 332, rab GDP dissociation inhibitor alpha-like (amino acid sequence: SEQ ID NO: 320, a base sequence encoding it: SEQ ID NO: 319) and SEQ ID NOs: 328 to 332 is disclosed. The nucleotide sequence encoding it (SEQ ID NO: 326) was identified.

[0173] Therefore, in the present application, the antigen of spot 17α may be any of the proteins selected from the group consisting of (17αA1-a) to (17αA1-e), (17αB1), (17αA2-a) to (17αA2-e), and (17αB2). (17αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 320 in which one or several amino acids have been deleted, substituted, inserted or added. (17αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 320. (17αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 319 have been deleted, substituted, inserted or added. (17αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 319. (17αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 319. (17αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 321 to 325, preferably a protein comprising at least two, three, four, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 321 to 325. (17αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 327 in which one or more amino acids have been deleted, substituted, inserted or added. (17αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 327. (17αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 326 have been deleted, substituted, inserted or added. (17αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 326. (17αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 326. (17αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 328 to 332, preferably at least two, three, four, or all of the amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 328 to 332.

[0174] The protein selected from the group consisting of (17αA1-a) to (17αA1-e), (17αB1), (17αA2-a) to (17αA2-e), and (17αB2) may be a protein that appears as a spot with a molecular weight of 20 to 90 kDa, preferably a molecular weight of around 30 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0175] Furthermore, the epitopes of the antigens (17αA1-a) to (17αA1-e) and (17αB1) are located at amino acids 171 to 185 (SEQ ID NO: 767) of SEQ ID NO: 320. When the antigen of spot 17α contains a mutation in the amino acid sequence of SEQ ID NO: 320, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 320.

[0176] Preferably, the protein that is the antigen of spot 17α is a protein having the amino acid sequence of SEQ ID NO: 320 (guanosine nucleotide diphosphate dissociation inhibitor 2 ) or a protein having the amino acid sequence of SEQ ID NO: 327 (rab GDP dissociation inhibitor alpha-like), or a protein that is a cause of soy allergy. become.

[0177] (18α) Spot 18α antigen Spot 18α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 335 to 339 were detected.

[0178] Furthermore, when the mass data obtained from the mass spectrometer for spot 18α was analyzed by collating it with the protein data of NCBI, it was found that the hypothetical protein GLYMA_10G028300 (amino acid sequence: SEQ ID NO: 334, base sequence encoding it: SEQ ID NO: 335) was a protein containing any of SEQ ID NOs: 335 to 339. No. 333) was identified.

[0179] Therefore, in the present application, the antigen of spot 18α is any one of proteins selected from the group consisting of (18αA-a) to (18αA-e) and (18αB): good. (18αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 334 in which one or more amino acids have been deleted, substituted, inserted or added. (18αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 334. (18αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 333 have been deleted, substituted, inserted or added. (18αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 333. (18αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 333. (18αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 335 to 339, preferably a protein comprising at least two, three, four, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 335 to 339.

[0180] The protein selected from the group consisting of (18αA-a) to (18αA-e) and (18αB) above may be a protein that appears as a spot with a molecular weight of 30 to 90 kDa, preferably a molecular weight of around 40 to 80 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0181] The epitopes of the antigen in spot 18α are located at amino acids 52 to 60 (SEQ ID NO: 750), 81 to 95 (SEQ ID NO: 768), 101 to 115 (SEQ ID NO: 771), 281 to 295 (SEQ ID NO: 772), and 491 to 500 (SEQ ID NO: 775) of SEQ ID NO: 334. The antigen in spot 18α may retain the sequence of SEQ ID NO: 334 for amino acids at positions corresponding to at least one region of the epitope.

[0182] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 18α may be the following mutant.

[0183] Of the epitope having the sequence of SEQ ID NO: 771, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 769 or 770. Therefore, in another preferred embodiment, the antigen of spot 18α may be one in which amino acids 101 to 115 in SEQ ID NO: 334 are the amino acid sequence of SEQ ID NO: 769 or 770.

[0184] Of the epitope having the sequence of SEQ ID NO: 775, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 773 or 774. Therefore, in another preferred embodiment, the antigen of spot 18α may be one in which amino acids 491 to 500 in SEQ ID NO: 334 are the amino acid sequence of SEQ ID NO: 773 or 774.

[0185] Preferably, the protein that is an antigen of spot 18α has an activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 334 (hypothetical protein GLYMA_10G028300). , or cause allergies to soy.

[0186] (19α) Spot 19α antigen Spot 19α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 342 to 346 were detected.

[0187] Furthermore, when the mass data obtained from a mass spectrometer for spot 19α was analyzed by comparing it with NCBI protein data, sucrose binding protein homolog S-64 (amino acid sequence: SEQ ID NO: 341, base sequence encoding it: SEQ ID NO: 340) was identified as a protein containing any of SEQ ID NOs: 342 to 346.

[0188] Therefore, in the present application, the antigen of spot 19α may be any protein selected from the group consisting of the following (19αA-a) to (19αA-e), and (19αB): (19αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 341 in which one or more amino acids have been deleted, substituted, inserted or added. (19αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 341. (19αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 340 have been deleted, substituted, inserted or added. (19αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 340. (19αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 340. (19αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 342 to 346, preferably a protein comprising at least two, three, four, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 342 to 346.

[0189] The protein selected from the group consisting of (19αA-a) to (19αA-e) and (19αB) above may be a protein that appears as a spot with a molecular weight of 30 to 90 kDa, preferably a molecular weight of around 40 to 80 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0190] The epitopes of the antigen in spot 19α are located at amino acids 191 to 205 (SEQ ID NO: 778), 475 to 489 (SEQ ID NO: 781), 81 to 95 (SEQ ID NO: 784), 436 to 450 (SEQ ID NO: 786), and 21 to 30 (SEQ ID NO: 787) of SEQ ID NO: 341. The antigen in spot 19α may retain the sequence of SEQ ID NO: 341 for amino acids at positions corresponding to at least one region of the epitope.

[0191] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 19α may be the following mutant.

[0192] Of the epitope having the sequence of SEQ ID NO: 778, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 776 or 778. Therefore, in another preferred embodiment, the antigen of spot 19α may be one in which amino acids 191 to 205 in SEQ ID NO: 341 are the amino acid sequence of SEQ ID NO: 776 or 778.

[0193] Of the epitope having the sequence of SEQ ID NO: 781, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 779 or 780. Therefore, in another preferred embodiment, the antigen of spot 19α may be one in which amino acids 475 to 489 in SEQ ID NO: 341 are the amino acid sequence of SEQ ID NO: 779 or 780.

[0194] Of the epitope having the sequence of SEQ ID NO: 784, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 782 or 783. Therefore, in another preferred embodiment, the antigen of spot 19α may be one in which amino acids 81 to 95 in SEQ ID NO: 341 are the amino acid sequence of SEQ ID NO: 782 or 783.

[0195] Preferably, the protein that is an antigen of spot 19α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 341 (sucrose binding protein homolog S-64), or causes allergy to soybean.

[0196] (25α) Spot 25α antigen Spot 25α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 349 to 365 were detected.

[0197] Furthermore, analysis of the mass data obtained from the mass spectrometer for spot 25α against the protein data of NCBI revealed that the protein containing any of SEQ ID NOS: 349 to 356 was succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial (amino acid sequence: SEQ ID NOS: 348, base sequence encoding it: SEQ ID NOS: 347). As a protein containing any one of SEQ ID NOS: 359 to 365, succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial (amino acid sequence: SEQ ID NOS: 358, base sequence encoding same: SEQ ID NOS: 357) was identified.

[0198] Therefore, in the present application, the antigen of spot 25α may be any of the proteins selected from the group consisting of (25αA1-a) to (25αA1-e), (25αB1), (25αA2-a) to (25αA2-e), and (25αB2). (25αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 348 in which one or more amino acids have been deleted, substituted, inserted or added. (25αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 348. (25αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 347 have been deleted, substituted, inserted or added. (25αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 347. (25αA1-e) Amino acids encoded by nucleic acids that hybridize under stringent conditions with nucleic acids consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 347 Proteins containing sequences. (25αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 349 to 356, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 349 to 356. (25αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 358 in which one or several amino acids have been deleted, substituted, inserted or added. (25αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 358. (25αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 357 have been deleted, substituted, inserted or added. (25αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 357. (25αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 357. (25αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 359 to 365, preferably a protein comprising at least 2, 3, 4, 5, 6, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 359 to 365.

[0199] The protein selected from the group consisting of (25αA1-a) to (25αA1-e), (25αB1), (25αA2-a) to (25αA2-e), and (25αB2) may be a protein that appears as a spot with a molecular weight of 20 to 90 kDa, preferably a molecular weight of around 30 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0200] Furthermore, the epitopes of the antigens (25αA1-a) to (25αA1-e) and (25αB1) are located at amino acids 241 to 255 (SEQ ID NO: 814) and amino acids 321 to 335 (SEQ ID NO: 815) of SEQ ID NO: 348. When the antigen of spot 25α contains a mutation in the amino acid sequence of SEQ ID NO: 348, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 348.

[0201] Preferably, the protein that is the antigen of spot 25α has activity equivalent to the protein having the amino acid sequence of SEQ ID NO: 348 or 358 (succinyl-CoA ligase [ADP-forming] subunit beta, mitochondrial), or is a cause of soy allergy. .

[0202] (26α) Spot 26α antigen Spot 26α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 368 to 409 were detected.

[0203] In addition, when the mass data obtained from the mass spectrometer for spot 26α was analyzed by collating it with the protein data of NCBI, it was found that the protein contained any one of SEQ ID NOs: 368 to 382. The following proteins were identified: phosphoglycerate kinase, cytosolic (amino acid sequence: SEQ ID NO: 367, nucleotide sequence encoding it: SEQ ID NO: 366); phosphoglycerate kinase, cytosolic (amino acid sequence: SEQ ID NO: 384, nucleotide sequence encoding it: SEQ ID NO: 383) as a protein containing any of SEQ ID NOs: 385 to 392; and phosphoglycerate kinase, cytosolic (amino acid sequence: SEQ ID NO: 394, nucleotide sequence encoding it: SEQ ID NO: 393) as a protein containing any of SEQ ID NOs: 395 to 409.

[0204] Therefore, in the present application, the antigen of spot 26α may be any of the proteins selected from the group consisting of (26αA1-a) to (26αA1-e), (26αB1), (26αA2-a) to (26αA2-e), (26αB2), (26αA3-a) to (26αA3-e), and (26αB3). (26αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 367 in which one or more amino acids have been deleted, substituted, inserted or added. (26αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 367. (26αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 366 have been deleted, substituted, inserted or added. (26αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 366. (26αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 366. (26αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 368 to 382, ​​preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of said amino acid sequences. Here, the amino acid sequence represented by any of SEQ ID NOs: 368 to 382 may have one or several amino acids deleted, substituted, inserted, or added. (26αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 384 in which one or more amino acids have been deleted, substituted, inserted or added. (26αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 384. (26αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 383 have been deleted, substituted, inserted or added. (26αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 383. (26αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 383. (26αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 385 to 392, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 385 to 392. (26αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 394 in which one or more amino acids have been deleted, substituted, inserted or added. (26αA3-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 394. (26αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 393 have been deleted, substituted, inserted or added. (26αA3-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 393. (26αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 393. (26αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 395 to 409, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of said amino acid sequences. Here, the amino acid sequence represented by any of SEQ ID NOs: 395 to 409 may have one or several amino acids deleted, substituted, inserted, or added.

[0205] The proteins selected from the group consisting of (26αA1-a) to (26αA1-e), (26αB1), (26αA2-a) to (26αA2-e), (26αB2), (26αA3-a) to (26αA3-e), and (26αB3) may be proteins that appear as spots with molecular weights of 20 to 90 kDa, preferably around 30 to 80 kDa, and isoelectric points of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigens" section above. Furthermore, the epitopes of the antigens (26αA1-a) to (26αA1-e) and (26αB1) are present at amino acids 121 to 135 (SEQ ID NO: 816) and 329 to 335 (SEQ ID NO: 819) of SEQ ID NO: 367. When the antigen of spot 26α contains a mutation in the amino acid sequence of SEQ ID NO: 367, the sequence of SEQ ID NO: 361 may be retained for the amino acids at positions corresponding to at least one region of the epitope.

[0206] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 26α may be the following mutant.

[0207] Of the epitope having the sequence of SEQ ID NO: 819, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 817 or 818. Therefore, in another preferred embodiment, when the antigen of spot 26α contains a mutation in the amino acid sequence of SEQ ID NO: 367, the antigen may be one in which amino acids 329 to 335 in SEQ ID NO: 367 are the amino acid sequence of SEQ ID NO: 817 or 818.

[0208] Preferably, the protein that is an antigen of spot 25α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 367, 384 or 394 (phosphoglycerate kinase, cytosolic), or causes allergy to soybean.

[0209] (27α) Spot 27α antigen Spot 27α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 412 to 427 were detected.

[0210] In addition, when the mass data obtained from the mass spectrometer for spot 27α was analyzed by collating it with the protein data of NCBI, it was identified as alcohol dehydrogenase 1 (amino acid sequence number 412 to 416) as a protein containing any one of SEQ ID NOs: 412 to 416. Alcohol dehydrogenase 1 (amino acid sequence: SEQ ID NO: 418, nucleotide sequence encoding it: SEQ ID NO: 417) was identified as a protein containing either of SEQ ID NOs: 419 or 420; and alcohol dehydrogenase 1-like (amino acid sequence: SEQ ID NO: 422, nucleotide sequence encoding it: SEQ ID NO: 421) was identified as a protein containing either of SEQ ID NOs: 423 to 427.

[0211] Therefore, in the present application, the antigen of spot 27α may be any of the proteins selected from the group consisting of (27αA1-a) to (27αA1-e), (27αB1), (27αA2-a) to (27αA2-e), (27αB2), (27αA3-a) to (27αA3-e), and (27αB3). (27αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 411 in which one or several amino acids have been deleted, substituted, inserted or added. (27αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 411. (27αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 410 have been deleted, substituted, inserted or added. (27αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 410. (27αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 410. (27αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 412 to 416, preferably at least two, three, four, or all of the amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 412 to 416. (27αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 418 in which one or more amino acids have been deleted, substituted, inserted or added. (27αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 418. (27αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 417 have been deleted, substituted, inserted or added. (27αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 417. (27αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 417. (27αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 419 and 420, preferably a protein comprising both of said amino acid sequences, wherein the amino acid sequence represented by either SEQ ID NO: 419 or 420 may have one or several amino acids deleted, substituted, inserted or added. (27αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 422 in which one or more amino acids have been deleted, substituted, inserted or added. (27αA3-b) Identification with the amino acid sequence shown in SEQ ID NO: 422 is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, Proteins that contain more than 8% and more than 99% of the amino acid sequence. (27αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 421 have been deleted, substituted, inserted or added. (27αA3-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 421. (27αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 421. (27αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 423 to 427, preferably a protein comprising at least two, three, four, or all of the amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 423 to 427.

[0212] The protein selected from the group consisting of (27αA1-a) to (27αA1-e), (27αB1), (27αA2-a) to (27αA2-e), (27αB2), (27αA3-a) to (27αA3-e), and (27αB3) may be a protein that appears as a spot with a molecular weight of 20 to 90 kDa, preferably a molecular weight of around 30 to 80 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section ``Identification of antigen.''

[0213] Furthermore, the epitopes of the antigens (27αA1-a) to (27αA1-e) and (27αB1) are located at amino acids 21 to 35 (SEQ ID NO: 820) of SEQ ID NO: 411. When the antigen of spot 27α contains a mutation in the amino acid sequence of SEQ ID NO: 411, the amino acids at positions corresponding to the regions of the epitopes may retain the sequence of SEQ ID NO: 411.

[0214] Preferably, the protein that is the antigen of spot 27α is a protein having the amino acid sequence of SEQ ID NO: 411 or 418 (alcohol dehydrogenase 1) or SEQ ID NO: 42 It has activity equivalent to that of a protein with the amino acid sequence of 2 (alcohol dehydrogenase 1-like), or it may cause allergies to soy.

[0215] (28α) Spot 28α antigen Spot 28α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 430 to 433 were detected.

[0216] In addition, for spot 28α, the mass data obtained from the mass spectrometer was analyzed by collating it with the protein data of NCBI, and it was found that the protein containing any of SEQ ID NOS: 430 to 433 was 35 kDa seed maturation protein isoform X1 (amino acid sequence: SEQ ID NOS: 429, The base sequence corresponding to this gene (SEQ ID NO: 428) was identified.

[0217] Therefore, in the present application, the antigen of spot 28α may be any protein selected from the group consisting of (28αA-a) to (28αA-e) and (28αB) below. (28αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 429 in which one or more amino acids have been deleted, substituted, inserted or added. (28αA-b) The amino acid sequence shown in SEQ ID NO: 429 has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more % or more, or 99% or more of the amino acid sequence of a protein. (28αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 428 have been deleted, substituted, inserted or added. (28αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 428. (28αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 428. (28αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 430 to 433, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 430 to 433.

[0218] The protein selected from the group consisting of (28αA-a) to (28αA-e) and (28αB) above may be a protein that appears as a spot with a molecular weight of 10 to 70 kDa, preferably around 20 to 60 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0219] Furthermore, the epitope of the antigen in spot 28α is located at amino acids 76 to 85 (SEQ ID NO: 820), 191 to 205 (SEQ ID NO: 826), 231 to 245 (SEQ ID NO: 829), 111 to 125 (SEQ ID NO: 830), 131 to 145 (SEQ ID NO: 831), 161 to 175 (SEQ ID NO: 832), 181 to 195 (SEQ ID NO: 833), 291 to 305 (SEQ ID NO: 834), and 295 to 309 (SEQ ID NO: 835) of SEQ ID NO: 429. The antigen in spot 28α may retain the sequence of SEQ ID NO: 429 for amino acids at positions corresponding to at least one region of the epitope.

[0220] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 28α may be the following mutant.

[0221] Of the epitope having the sequence of SEQ ID NO: 823, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 821 or 822. Therefore, in another preferred embodiment, the antigen of spot 28α may be one in which amino acids 76 to 85 in SEQ ID NO: 429 are the amino acid sequence of SEQ ID NO: 821 or 822.

[0222] Of the epitope having the sequence of SEQ ID NO: 826, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 824 or 825. Therefore, in another preferred embodiment, the antigen of spot 28α may be one in which amino acids 191 to 205 in SEQ ID NO: 429 are the amino acid sequence of SEQ ID NO: 824 or 825.

[0223] Of the epitope having the sequence of SEQ ID NO: 829, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 827 or 828. Therefore, in another preferred embodiment, the antigen of spot 28α may be one in which amino acids 231 to 2455 in SEQ ID NO: 429 are the amino acid sequence of SEQ ID NO: 827 or 828.

[0224] Preferably, the protein that is the antigen of spot 28α has an activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 422 (35 kDa seed maturation protein isoform X1). It may cause allergies to soy.

[0225] (29α, 30α, 31α, 32α, 33α) Antigens in spots 29α to 33α As a result of performing sequence identification by mass spectrometry for spots 29α to 33α, the amino acid sequences of SEQ ID NOs: 436 to 451 were detected.

[0226] Furthermore, for spots 27α to 33α, the mass data obtained from the mass spectrometer was analyzed by collating it with the protein data of NCBI, and it was found that glyceraldehyde-3-phosphate dehydrogenase isoform X1 (amino acid sequence 436 to 439) was a protein containing any of SEQ ID NOs: 436 to 439. 435, its encoding base sequence: SEQ ID NO: 434), and glyceraldehyde-3-phosphate dehydrogenase, cytosolic (glyceraldehyde-3-phosphate dehydrogenase, cytosolic) as a protein containing any one of SEQ ID NOs: 442 to 445. ) (amino acid sequence: SEQ ID NO: 441, nucleotide sequence encoding it: SEQ ID NO: 440), and uncharacterized protein LOC100782924 (amino acid sequence: SEQ ID NO: 447, nucleotide sequence encoding it: SEQ ID NO: 446) were identified as proteins containing any of SEQ ID NOs: 448 to 451.

[0227] Therefore, in the present application, the antigens of spots 29α to 33α may be any of the proteins selected from the group consisting of (29-33αA1-a) to (29-33αA1-e), (29-33αB1), (29-33αA2-a) to (29-33αA2-e), (29-33αB2), (29-33αA3-a) to (29-33αA3-e), and (29-33αB3). (29-33αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 435 in which one or several amino acids have been deleted, substituted, inserted or added. (29-33αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 435. (29-33αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 434 have been deleted, substituted, inserted or added. (29-33αA1-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identity to the nucleotide sequence shown in SEQ ID NO: 434. (29-33αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 434. (29-33αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 436 to 439, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 436 to 439. (29-33αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 441 in which one or several amino acids have been deleted, substituted, inserted or added. (29-33αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 441. (29-33αA2-c) One or several nucleotides are deleted or substituted in SEQ ID NO: 440 A protein containing an amino acid sequence encoded by a substituted, inserted or added base sequence. (29-33αA2-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identity to the nucleotide sequence shown in SEQ ID NO: 440. (29-33αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 440. (29-33αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 442 to 445, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 442 to 445. (29-33αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 447 in which one or several amino acids have been deleted, substituted, inserted or added. (29-33αA3-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 447. (29-33αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 446 have been deleted, substituted, inserted or added. (29-33αA3-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the nucleotide sequence shown in SEQ ID NO: 446. (29-33αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 446. (29-33αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 448 to 451, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 448 to 451.

[0228] The protein selected from the group consisting of (29-33αA1-a) to (29-33αA1-e), (29-33αB1), (29-33αA2-a) to (29-33αA2-e), (29-33αB2), (29-33αA3-a) to (29-33αA3-e), and (29-33αB3) may be a protein that appears as a spot with a molecular weight of 10 to 70 kDa, preferably a molecular weight of around 20 to 60 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section ``Identification of antigen.''

[0229] Furthermore, the epitopes of the antigens (29-33αA1-a) to (29-33αA1-e) and (29-33αB1) are located at amino acids 66 to 75 (SEQ ID NO: 838) and amino acids 301 to 315 (SEQ ID NO: 839) of SEQ ID NO: 435. When the antigen of spot 29-33α contains a mutation in the amino acid sequence of SEQ ID NO: 435, the sequence of SEQ ID NO: 435 may be retained for the amino acids at positions corresponding to at least one region of the epitope.

[0230] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 29-33α may be the following mutant.

[0231] Of the epitope having the sequence of SEQ ID NO: 838, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 836 or 837. Therefore, in another preferred embodiment, when the antigen of spot 29-33α contains a mutation in the amino acid sequence of SEQ ID NO: 435, the antigen may be one in which amino acids 66 to 75 in SEQ ID NO: 435 are the amino acid sequence of SEQ ID NO: 836 or 837.

[0232] Preferably, the protein that is an antigen of spots 29α to 33α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 435 (glyceraldehyde-3-phosphate dehydrogenase isoform X1), a protein having the amino acid sequence of SEQ ID NO: 441 (glyceraldehyde-3-phosphate dehydrogenase, cytosolic), or a protein having the amino acid sequence of SEQ ID NO: 447 (uncharacterized protein LOC100782924), or causes soy allergy.

[0233] (34α) Spot 34α antigen As a result of performing sequence identification by mass spectrometry for spot 34α, the amino acid sequences of SEQ ID NOs: 454 to 458 were detected.

[0234] Furthermore, when the mass data obtained from the mass spectrometer for spot 34α was analyzed by comparing it with NCBI protein data, bifunctional UDP-glucose 4-epimerase and UDP-xylose 4-epimerase 1-like (amino acid sequence: SEQ ID NO: 453, nucleotide sequence encoding it: SEQ ID NO: 452) was identified as a protein containing SEQ ID NO: 454, and uncharacterized protein LOC100803483 (amino acid sequence: SEQ ID NO: 456, nucleotide sequence encoding it: SEQ ID NO: 455) was identified as a protein containing either SEQ ID NO: 457 or 458.

[0235] Therefore, in the present application, the antigen of spot 34α may be any of the proteins selected from the group consisting of (34αA1-a) to (34αA1-e), (34αB1), (34αA2-a) to (34αA2-e), and (34αB2). (34αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 453 in which one or more amino acids have been deleted, substituted, inserted or added. (34αA1-b) A protein containing an amino acid sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence shown in SEQ ID NO: 453. (34αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 452 have been deleted, substituted, inserted or added. (34αA1-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 452. (34αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 452. (34αB1) A protein comprising the amino acid sequence shown in SEQ ID NO: 454. In this case, the amino acid sequence shown in SEQ ID NO: 464 may have one or more amino acids deleted, substituted, inserted or added. (34αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 456 in which one or more amino acids have been deleted, substituted, inserted or added. (34αA2-b) Identification with the amino acid sequence shown in SEQ ID NO: 456 is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, Proteins that contain more than 8% and more than 99% of the amino acid sequence. (34αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 455 have been deleted, substituted, inserted or added. (34αA2-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 455. (34αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 455. (34αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 457 and 458, preferably a protein comprising both of said amino acid sequences. In this regard, the amino acid sequence shown in either SEQ ID NO: 457 or 458 may have one or several amino acids deleted, substituted, inserted or added.

[0236] The protein selected from the group consisting of (34αA1-a) to (34αA1-e), (34αB1), (34αA2-a) to (34αA2-e), and (34αB2) may be a protein that appears as a spot with a molecular weight of 10 to 70 kDa, preferably around 20 to 60 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0237] Furthermore, the epitopes of the antigens (34αA1-a) to (34αA1-e) and (34αB1) are located at amino acids 61 to 75 (SEQ ID NO: 842), 31 to 45 (SEQ ID NO: 843), 141 to 155 (SEQ ID NO: 844), 221 to 235 (SEQ ID NO: 845), and 231 to 245 (SEQ ID NO: 846) of SEQ ID NO: 454. When the antigen of spot 34α contains a mutation in the amino acid sequence of SEQ ID NO: 454, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 454.

[0238] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 34α may be the following mutant.

[0239] Of the epitope having the sequence of SEQ ID NO: 842, the site important for binding to IgE antibodies in allergy patients is the site represented by amino acids other than X in SEQ ID NO: 840 or 841. Therefore, in another preferred embodiment, when the antigen of spot 34α contains a mutation in the amino acid sequence of SEQ ID NO: 454, the antigen may be one in which amino acids 61 to 75 in SEQ ID NO: 454 are the amino acid sequence of SEQ ID NO: 840 or 841. Preferably, the protein that is the antigen of spot 34α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 453 (bifunctional UDP-glucose 4-epimerase and UDP-xylose 4-epimerase 1-like) or the protein having the amino acid sequence of SEQ ID NO: 456 (uncharacterized protein LOC100803483), or causes soybean allergy.

[0240] (35α) Spot 35α antigen As a result of performing sequence identification by mass spectrometry for spot 35α, the amino acid sequences of SEQ ID NOs: 461 to 477 were detected.

[0241] Furthermore, when the mass data obtained from the mass spectrometer for spot 35α was analyzed by collating it with the protein data of NCBI, it was identified as a protein containing any of SEQ ID NOS: 461 to 466, which was identified as elongation factor 1-alpha (elongation factor 1-alpha ) (amino acid sequence: SEQ ID NO: 460, nucleotide sequence encoding it: SEQ ID NO: 459), elongation factor 1-alpha as a protein comprising any one of SEQ ID NOs: 469 to 471 (amino acid sequence: SEQ ID NO: 468, nucleotide sequence encoding it: SEQ ID NO: 467), elongation factor-1A isoform X1 as a protein comprising any one of SEQ ID NOs: 474 to 477 (amino acid sequence: SEQ ID NO: 474, ... The sequence: SEQ ID NO: 473, and the base sequence encoding it: SEQ ID NO: 472) were identified.

[0242] Therefore, in the present application, the antigen of spot 35α may be any of the proteins selected from the group consisting of (35αA1-a) to (35αA1-e), (35αB1), (35αA2-a) to (35αA2-e), (35αB2), (35αA3-a) to (35αA3-e), and (35αB3). (35αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 460 in which one or more amino acids have been deleted, substituted, inserted or added. (35αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 460. (35αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 459 have been deleted, substituted, inserted or added. (35αA1-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 459. (35αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 459. (35αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 461 to 466, preferably at least two, three, four, five, or all of said amino acid sequences, wherein the amino acid sequence represented by any of SEQ ID NOs: 412 to 416 may have one or more amino acids deleted, substituted, inserted, or added. (35αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 468 in which one or more amino acids have been deleted, substituted, inserted or added. (35αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 468. (35αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 467 have been deleted, substituted, inserted or added. (35αA2-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 467. (35αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 467. (35αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 469 to 471, preferably at least two or all of the amino acid sequences, wherein the amino acid sequence represented by any of SEQ ID NOs: 469 to 471 may have one or several amino acids deleted, substituted, inserted or added. (35αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 473 in which one or more amino acids have been deleted, substituted, inserted or added. (35αA3-b) 70% or more identity with the amino acid sequence shown in SEQ ID NO: 473, preferably or a protein containing 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more of the amino acid sequence. (35αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 472 have been deleted, substituted, inserted or added. (35αA3-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 472. (35αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 472. (35αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 474 to 477, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 474 to 477.

[0243] The protein selected from the group consisting of (35αA1-a) to (35αA1-e), (35αB1), (35αA2-a) to (35αA2-e), (35αB2), (35αA3-a) to (35αA3-e), and (35αB3) may be a protein that appears as a spot with a molecular weight of 20 to 90 kDa, preferably around 30 to 80 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0244] Furthermore, the epitopes of the antigens (35αA1-a) to (35αA1-e) and (35αB1) are located at amino acids 31 to 45 (SEQ ID NO: 849), 121 to 135 (SEQ ID NO: 850), 192 to 220 (SEQ ID NO: 853), and 216 to 225 (SEQ ID NO: 856) of SEQ ID NO: 460. When the antigen of spot 35α contains a mutation in the amino acid sequence of SEQ ID NO: 460, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 460.

[0245] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 35α may be the following mutant.

[0246] Of the epitope having the sequence of SEQ ID NO: 849, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 847 or 848. Therefore, in another preferred embodiment, when the antigen of spot 35α contains a mutation in the amino acid sequence of SEQ ID NO: 460, the antigen may be one in which amino acids 31 to 45 in SEQ ID NO: 460 are the amino acid sequence of SEQ ID NO: 847 or 848.

[0247] Of the epitope having the sequence of SEQ ID NO: 853, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 851 or 852. Therefore, in another preferred embodiment, when the antigen of spot 35α contains a mutation in the amino acid sequence of SEQ ID NO: 460, the antigen may be one in which amino acids 192 to 220 in SEQ ID NO: 460 are the amino acid sequence of SEQ ID NO: 851 or 852.

[0248] Of the epitopes having the sequence of SEQ ID NO: 856, the site important for binding to IgE antibodies of allergic patients is the site represented by an amino acid other than X in SEQ ID NO: 854 or 855. Therefore, in another preferred embodiment, when the antigen of spot 35α contains a mutation in the amino acid sequence of SEQ ID NO: 460, the antigen may be one in which amino acids 216 to 225 in SEQ ID NO: 460 are the amino acid sequence of SEQ ID NO: 854 or 855.

[0249] Preferably, the protein that is the antigen of spot 35α is a protein having the amino acid sequence of SEQ ID NO: 460 or 468 (elongation factor 1-alpha) or SEQ ID NO: 4 Equivalent to a protein with a 73 amino acid sequence (elongation factor-1A isoform X1) It has activity or causes allergies to soy.

[0250] (36α, 37α) Spot 36α and 37α antigens As a result of performing sequence identification by mass spectrometry for spots 36α and 37α, the amino acid sequences of SEQ ID NOs: 480 to 493 were detected.

[0251] Furthermore, for spots 36α and 37α, the mass data obtained from the mass spectrometer was analyzed by collating it with the protein data of NCBI. As a result, seed maturation protein PM34 (amino acid sequence: SEQ ID NO: 479, nucleotide sequence encoding it: SEQ ID NO: 478) was identified as a protein containing any of SEQ ID NOs: 480 to 483, uncharacterized protein LOC100809384 (amino acid sequence: SEQ ID NO: 485, nucleotide sequence encoding it: SEQ ID NO: 484) was identified as a protein containing any of SEQ ID NOs: 486 and 487, and hypothetical protein GLYMA_10G155300 (amino acid sequence: SEQ ID NO: 489, nucleotide sequence encoding it: SEQ ID NO: 4490 to 493) was identified. The coding sequence (SEQ ID NO: 488) was identified.

[0252] Therefore, in the present application, the antigens of spots 36α and 37α may be any of proteins selected from the group consisting of (36,37αA1-a) to (36,37αA1-e), (36,37αB1), (36,37αA2-a) to (36,37αA2-e), (36,37αB2), (36,37αA3-a) to (36,37αA3-e), and (36,37αB3). (36,37αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 479 in which one or more amino acids have been deleted, substituted, inserted or added. (36,37αA1-b) A protein comprising an amino acid sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence set forth in SEQ ID NO: 479. (36,37αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 478 have been deleted, substituted, inserted or added. (36,37αA1-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the nucleotide sequence shown in SEQ ID NO: 478. (36,37αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 478. (36,37αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 480 to 483, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in any of the amino acid sequences represented by SEQ ID NOs: 480 to 483. (36,37αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 485 in which one or more amino acids have been deleted, substituted, inserted or added. (36,37αA2-b) A protein containing an amino acid sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence shown in SEQ ID NO: 485. (36,37αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 484 have been deleted, substituted, inserted or added. (36,37αA2-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the nucleotide sequence shown in SEQ ID NO: 484. (36,37αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 484. (36,37αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 486 and 487, preferably a protein comprising both of said amino acid sequences, wherein the amino acid sequence represented by either SEQ ID NO: 486 or 487 may have one or several amino acids deleted, substituted, inserted or added. (36,37αA3-a) A protein comprising the amino acid sequence of SEQ ID NO: 489 in which one or several amino acids have been deleted, substituted, inserted or added. (36,37αA3-b) A protein containing an amino acid sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence shown in SEQ ID NO: 489. (36,37αA3-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 488 have been deleted, substituted, inserted or added. (36,37αA3-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the nucleotide sequence shown in SEQ ID NO: 488. (36,37αA3-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 488. (36,37αB3) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 490 to 493, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 490 to 493.

[0253] The protein selected from the group consisting of (36,37αA1-a) to (36,37αA1-e), (36,37αB1), (36,37αA2-a) to (36,37αA2-e), (36,37αB2), (36,37αA3-a) to (36,37αA3-e), and (36,37αB3) may be a protein that appears as a spot with a molecular weight of 10 to 70 kDa, preferably a molecular weight of around 20 to 60 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0254] Furthermore, the epitopes of the antigens (36,37αA1-a) to (36,37αA1-e) and (36,37αB1) are located at amino acids 141 to 155 (SEQ ID NO: 857), amino acids 231 to 245 (SEQ ID NO: 858), and amino acids 7 to 14 (SEQ ID NO: 861) of SEQ ID NO: 479. When the antigens of spots 36α and 37α contain mutations in the amino acid sequence of SEQ ID NO: 479, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 479.

[0255] In addition, sensitivity (the degree to which patients can be judged as positive) and specificity (the degree to which healthy people are not judged as positive) From the viewpoint of improving b), the antigens of spots 36α and 37α may be the following mutants:

[0256] Of the epitope having the sequence of SEQ ID NO: 861, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 859 or 860. Therefore, in another preferred embodiment, when the antigen in spots 36α and 37α contains a mutation in the amino acid sequence of SEQ ID NO: 479, the antigen may be one in which amino acids 7 to 14 in SEQ ID NO: 479 are the amino acid sequence of SEQ ID NO: 859 or 860.

[0257] Preferably, the protein that is an antigen of spots 36α and 37α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 479 (seed maturation protein PM34), a protein having the amino acid sequence of SEQ ID NO: 485 (uncharacterized protein LOC100809384), or a protein having the amino acid sequence of SEQ ID NO: 489 (hypothetical protein GLYMA_10G155300), or causes soy allergy.

[0258] (38α) Spot 38α antigen As a result of performing sequence identification by mass spectrometry for spot 38α, the amino acid sequences of SEQ ID NOs: 496 to 513 were detected.

[0259] Furthermore, when the mass data obtained from the mass spectrometer for spot 38α was analyzed by comparing it with the protein data from NCBI, seed biotin-containing protein SBP65-like isoform X1 (amino acid sequence: SEQ ID NO: 495, base sequence encoding it: SEQ ID NO: 494) was identified as a protein containing any of SEQ ID NOs: 496 to 513.

[0260] Therefore, in the present application, the antigen of spot 38α may be any protein selected from the group consisting of the following (38αA-a) to (38αA-e) and (38αB): (38αA-a) A protein comprising an amino acid sequence in which one or more amino acids are deleted, substituted, inserted or added in SEQ ID NO: 495. (38αA-b) A protein containing an amino acid sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence shown in SEQ ID NO: 495. (38αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 494 have been deleted, substituted, inserted or added. (38αA-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 494. (38αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 494. (38αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 496 to 513, preferably a protein comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or all of said amino acid sequences. Here, the amino acid sequence represented by any of SEQ ID NOs: 496 to 513 may have one or several amino acids deleted, substituted, inserted, or added.

[0261] A compound selected from the group consisting of (38αA-a) to (38αA-e) and (38αB) The protein to be detected may be a protein that appears as a spot with a molecular weight of 70 to 170 kDa, preferably a molecular weight of about 80 to 160 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0262] Furthermore, the epitope of the antigen of spot 38α is present at amino acids 440 to 446 or 574 to 580 (SEQ ID NO: 864), amino acids 71 ​​to 80 (SEQ ID NO: 867), amino acids 521 to 535 (SEQ ID NO: 869), amino acids 1 to 15 (SEQ ID NO: 871), amino acids 31 to 45 (SEQ ID NO: 874), amino acids 221 to 235 (SEQ ID NO: 877), amino acids 461 to 470 (SEQ ID NO: 882), amino acids 481 to 490 (SEQ ID NO: 884), amino acids 821 to 835 (SEQ ID NO: 887), amino acids 861 to 870 (SEQ ID NO: 889), and amino acids 1031 to 1040 (SEQ ID NO: 892) of SEQ ID NO: 495. The antigen of spot 38α may retain the sequence of SEQ ID NO: 495 for amino acids at positions corresponding to at least one region of the epitope.

[0263] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 38α may be the following mutant.

[0264] Of the epitope having the sequence of SEQ ID NO: 864, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 862. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 440 to 446 and / or 574 to 580 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 862.

[0265] Of the epitope having the sequence of SEQ ID NO: 867, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 865 or 866. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 71 ​​to 80 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 865 or 866.

[0266] Of the epitope having the sequence of SEQ ID NO: 869, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 868. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 521 to 535 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 868.

[0267] Of the epitope having the sequence of SEQ ID NO: 871, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 870. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 1 to 15 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 870.

[0268] Of the epitope having the sequence of SEQ ID NO: 874, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 872 or 873. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 31 to 45 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 872 or 873.

[0269] Of the epitopes having the sequence of SEQ ID NO: 877, the site important for binding to IgE antibodies of allergy patients is the site represented by amino acids other than X in SEQ ID NO: 875 or 876. Therefore, in another preferred embodiment, the antigen of spot 38α is a site in which amino acids 221 to 235 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 875 or 876. It may be something.

[0270] Of the epitope having the sequence of SEQ ID NO: 880, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 878 or 879. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 311 to 325 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 878 or 879.

[0271] Of the epitope having the sequence of SEQ ID NO: 882, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 881. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 461 to 470 in SEQ ID NO: 495 have the amino acid sequence of SEQ ID NO: 881.

[0272] Of the epitope having the sequence of SEQ ID NO: 884, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 883. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 481 to 490 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 883.

[0273] Of the epitope having the sequence of SEQ ID NO: 887, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 885 or 886. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 821 to 835 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 885 or 886.

[0274] Of the epitope having the sequence of SEQ ID NO: 889, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 888. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 861 to 870 in SEQ ID NO: 495 have the amino acid sequence of SEQ ID NO: 888.

[0275] Of the epitope having the sequence of SEQ ID NO: 892, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 890 or 891. Therefore, in another preferred embodiment, the antigen of spot 38α may be one in which amino acids 1031 to 1040 in SEQ ID NO: 495 are the amino acid sequence of SEQ ID NO: 890 or 891.

[0276] Preferably, the protein that is an antigen of spot 38α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 495 (seed biotin-containing protein SBP65-like isoform X1) or causes allergy to soybeans.

[0277] (39α) Spot 39α antigen As a result of performing sequence identification by mass spectrometry for spot 39α, the amino acid sequence of SEQ ID NO: 516 was detected.

[0278] In addition, when the mass data obtained from a mass spectrometer for spot 39α was analyzed by comparing it with NCBI protein data, ATP synthase subunit O, mitochondrial-like (amino acid sequence: SEQ ID NO: 515, base sequence encoding it: SEQ ID NO: 514) was identified as a protein containing SEQ ID NO: 516.

[0279] Therefore, in the present application, the antigens of spot 39α are as follows: (39αA-a) to (39α Ae), and (39αB). (39αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 515 in which one or more amino acids have been deleted, substituted, inserted or added. (39αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 515. (39αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 514 have been deleted, substituted, inserted or added. (39αA-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 514. (39αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 514. (39αB) A protein comprising the amino acid sequence shown in SEQ ID NO: 516. In this case, the amino acid sequence shown in SEQ ID NO: 516 may have one or more amino acids deleted, substituted, inserted or added.

[0280] The protein selected from the group consisting of (39αA-a) to (39αA-e) and (39αB) above may be a protein that appears as a spot with a molecular weight of 5 to 60 kDa, preferably around 10 to 50 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0281] The epitope of the antigen in spot 39α is located at amino acids 71 ​​to 85 (SEQ ID NO: 895) of SEQ ID NO: 515. The antigen in spot 39α may retain the sequence in SEQ ID NO: 515 for the amino acids at positions corresponding to the region of the epitope.

[0282] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 39α may be the following mutant.

[0283] Of the epitope having the sequence of SEQ ID NO: 895, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 893 or 894. Therefore, in another preferred embodiment, the antigen of spot 39α may be one in which amino acids 71 ​​to 85 in SEQ ID NO: 515 are the amino acid sequence of SEQ ID NO: 893 or 894.

[0284] Preferably, the protein that is an antigen of spot 39α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 515 (ATP synthase subunit O, mitochondrial-like), or causes allergy to soybean.

[0285] (40α, 56α) Spot 40α, 56α antigens As a result of identifying the sequences of spots 40α and 56α by mass spectrometry, the amino acid sequences of SEQ ID NO: 519 and SEQ ID NO: 520 were detected.

[0286] Furthermore, for spots 40α and 56α, the mass data obtained from the mass spectrometer was analyzed by collating it with the protein data of NCBI, and it was found that the protein containing either SEQ ID NO: 519 or 520 was P24 oleosin isoform A (P24 oleosin isoform A ) (amino acid sequence: SEQ ID NO: 518, base sequence encoding same: SEQ ID NO: 517), Identified.

[0287] Therefore, in the present application, the antigens of spots 40α and 56α may be any of proteins selected from the group consisting of (40,56αA-a) to (40,56αA-e) and (40,56αB) below. (40,56αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 518 in which one or more amino acids have been deleted, substituted, inserted or added. (40,56αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 518. (40,56αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 517 have been deleted, substituted, inserted or added. (40,56αA-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 517. (40,56αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 517. (40,56αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 519 and 520, preferably a protein comprising both of said amino acid sequences. In this regard, the amino acid sequence shown in either SEQ ID NO: 519 or 520 may have one or several amino acids deleted, substituted, inserted or added.

[0288] The protein selected from the group consisting of (40,56αA-a) to (40,56αA-e) and (40,56αB) may be a protein that appears as a spot with a molecular weight of 5 to 60 kDa, preferably around 10 to 50 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0289] The epitopes of the antigens in spots 40α and 56α are located at amino acids 35 to 39 (SEQ ID NO: 898), 191 to 205 (SEQ ID NO: 899), and 214 to 222 (SEQ ID NO: 902) of SEQ ID NO: 518. The antigens in spots 40α and 56α may retain the sequence of SEQ ID NO: 518 for the amino acids at positions corresponding to the regions of the epitopes.

[0290] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigens of spots 40α and 56α may be the following mutants.

[0291] Of the epitope having the sequence of SEQ ID NO: 898, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 896 or 897. Therefore, in another preferred embodiment, the antigen of spots 40α, 56α may be one in which amino acids 35 to 39 in SEQ ID NO: 518 are the amino acid sequence of SEQ ID NO: 896 or 897.

[0292] Of the epitope having the sequence of SEQ ID NO: 902, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 900 or 901. Therefore, in another preferred embodiment, the antigen of spots 40α, 56α may be one in which amino acids 214 to 2229 in SEQ ID NO: 518 are the amino acid sequence of SEQ ID NO: 900 or 901.

[0293] Preferably, the protein that is an antigen of spot 40α or 56α has an activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 518 (P24 oleosin isoform A), or , which can cause soy allergies.

[0294] (41α) Spot 41α antigen As a result of performing sequence identification by mass spectrometry for spot 41α, the amino acid sequence of SEQ ID NO: 523 was detected.

[0295] Furthermore, when the mass data obtained from a mass spectrometer for spot 41α was analyzed by comparing it with NCBI protein data, the protein containing sequence number 523 was identified as uncharacterized protein At3g49720-like isoform X2 (amino acid sequence: sequence number 522, nucleotide sequence encoding it: sequence number 521).

[0296] Therefore, in the present application, the antigen of spot 41α may be any protein selected from the group consisting of (41αA-a) to (41αA-e) and (41αB) below. (41αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 522 in which one or more amino acids have been deleted, substituted, inserted or added. (41αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 522. (41αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 521 have been deleted, substituted, inserted or added. (41αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 521. (41αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 521. (41αB) A protein comprising the amino acid sequence shown in SEQ ID NO: 523. In this case, the amino acid sequence shown in SEQ ID NO: 523 may have one or several amino acids deleted, substituted, inserted or added.

[0297] The protein selected from the group consisting of (41αA-a) to (41αA-e) and (41αB) above may be a protein that appears as a spot with a molecular weight of 5 to 60 kDa, preferably around 10 to 50 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0298] The epitope of the antigen of spot 41α is located at amino acids 111 to 125 (SEQ ID NO: 903) of SEQ ID NO: 522. The antigen of spot 41α may retain the sequence of SEQ ID NO: 522 for the amino acids at positions corresponding to the region of the epitope.

[0299] Preferably, the protein that is an antigen of spot 41α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 515 (ATP synthase subunit O, mitochondrial-like), or causes allergy to soybean.

[0300] (42α, 43α) Spot 42α and 43α antigens As a result of performing sequence identification by mass spectrometry for spots 42α and 43α, the amino acid sequences of SEQ ID NOs: 526 to 539 were detected.

[0301] Furthermore, for spots 42α and 43α, the mass data obtained from the mass spectrometer was analyzed by collating it with the protein data of NCBI. As a result, superoxide dismutase [Mn], mitochondrial (amino acid sequence: SEQ ID NO: 525, nucleotide sequence encoding it: SEQ ID NO: 524) was identified as a protein containing any of SEQ ID NOs: 526 to 531, and hypothetical protein GLYMA_04G221300 (amino acid sequence: SEQ ID NO: 533, nucleotide sequence encoding it: SEQ ID NO: 534 to 539) was identified as a protein containing any of SEQ ID NOs: 534 to 539. 532) was identified.

[0302] Therefore, in the present application, the antigens of spots 42α and 43α may be any of the proteins selected from the group consisting of (42,43αA1-a) to (42,43αA1-e), (42,43αB1), (42,43αA2-a) to (42,43αA2-e), and (42,43αB2). (42,43αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 525 in which one or more amino acids have been deleted, substituted, inserted or added. (42,43αA1-b) A protein comprising an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 525. (42,43αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or several nucleotides in SEQ ID NO: 524 have been deleted, substituted, inserted or added. (42,43αA1-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having 70% or more identity, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identity to the nucleotide sequence shown in SEQ ID NO: 524. (42,43αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 524. (42, 43αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 526 to 531, preferably at least two, three, four, five, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 526 to 531. (42,43αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 533 in which one or more amino acids have been deleted, substituted, inserted or added. (42,43αA2-b) A protein containing an amino acid sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the amino acid sequence shown in SEQ ID NO: 533. (42,43αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 532 have been deleted, substituted, inserted or added. (42,43αA2-d) A protein comprising an amino acid sequence encoded by a nucleotide sequence having an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the nucleotide sequence shown in SEQ ID NO: 532. (42,43αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 532. (42,43αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 534 to 539, preferably at least 2, 3, 4 or 5 of the amino acid sequence , 5, or all of the sequences, wherein the amino acid sequence shown in any of SEQ ID NOs: 534 to 539 may have one or several amino acids deleted, substituted, inserted, or added.

[0303] The protein selected from the group consisting of (42,43αA1-a) to (42,43αA1-e), (42,43αB1), (42,43αA2-a) to (42,43αA2-e), and (42,43αB2) may be a protein that appears as a spot with a molecular weight of 5 to 60 kDa, preferably around 10 to 50 kDa, and an isoelectric point of 5.5 to 10.5, preferably 6.0 to 10.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0304] Furthermore, the epitopes of the antigens (42,43αA1-a) to (42,43αA1-e) and (42,43αB1) are located at amino acids 227 to 241 (SEQ ID NO: 906) of SEQ ID NO: 525. When the antigens of spots 42α and 43α contain mutations in the amino acid sequence of SEQ ID NO: 525, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 525.

[0305] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigens of spots 42α and 43α may be the following mutants.

[0306] Of the epitope having the sequence of SEQ ID NO: 906, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 904 or 905. Therefore, in another preferred embodiment, when the antigen in spots 42α and 43α contains a mutation in the amino acid sequence of SEQ ID NO: 525, the antigen may be one in which amino acids 227 to 241 in SEQ ID NO: 525 are the amino acid sequence of SEQ ID NO: 904 or 905.

[0307] Preferably, the protein that is an antigen of spots 42α and 43α has activity equivalent to that of a protein having the amino acid sequence of SEQ ID NO: 525 (superoxide dismutase [Mn], mitochondrial) or a protein having the amino acid sequence of SEQ ID NO: 533 (hypothetical protein GLYMA_04G221300), or causes soy allergy.

[0308] (45α) Spot 45α antigen Spot 45α was subjected to sequence identification by mass spectrometry, and the amino acid sequences of SEQ ID NOs: 542 to 551 were detected.

[0309] Furthermore, when the mass data obtained from the mass spectrometer for spot 45α was analyzed by collating it with the protein data of NCBI, it was identified as uncharacterized protein LOC100499771 (amino acid sequence: SEQ ID NO: 541, base sequence encoding it: SEQ ID NO: 540) as a protein containing any of SEQ ID NOs: 542 to 545, and hypothetical protein GLYMA_09G192800 (amino acid sequence: SEQ ID NO: 548 to 551) as a protein containing any of SEQ ID NOs: 548 to 551. The sequence: SEQ ID NO: 547, and the base sequence encoding it: SEQ ID NO: 546) were identified.

[0310] Therefore, in the present application, the antigen of spot 45α may be any of the proteins selected from the group consisting of (45αA1-a) to (45αA1-e), (45αB1), (45αA2-a) to (45αA2-e), and (45αB2). (45αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 541 in which one or more amino acids have been deleted, substituted, inserted or added. (45αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 541. (45αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 540 have been deleted, substituted, inserted or added. (45αA1-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 540. (45αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 540. (45αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 542 to 545, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 542 to 545. (45αA2-a) A protein comprising the amino acid sequence of SEQ ID NO: 547 in which one or more amino acids have been deleted, substituted, inserted or added. (45αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 547. (45αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 546 have been deleted, substituted, inserted or added. (45αA2-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 546. (45αA2-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 546. (45αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 548 to 551, preferably a protein comprising at least two, three, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 548 to 551.

[0311] The protein selected from the group consisting of (45αA1-a) to (45αA1-e), (45αB1), (45αA2-a) to (45αA2-e), and (45αB2) may be a protein that appears as a spot with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0312] Furthermore, the epitopes of the antigens (45αA1-a) to (45αA1-e) and (45αB1) are located at amino acids 11 to 25 (SEQ ID NO: 910), amino acids 51 to 65 (SEQ ID NO: 911), and amino acids 111 to 125 (SEQ ID NO: 912) of SEQ ID NO: 541. When the antigen of spot 45α contains a mutation in the amino acid sequence of SEQ ID NO: 541, the amino acids at positions corresponding to at least one region of the epitope may retain the sequence of SEQ ID NO: 541.

[0313] Preferably, the protein that is the antigen of spot 45α is a protein having the amino acid sequence of SEQ ID NO: 541 (uncharacterized protein LOC100499771) or SEQ ID NO: 54 It has activity equivalent to that of a protein with the amino acid sequence of 7 (hypothetical protein GLYMA_09G192800), or may cause soy allergies.

[0314] (46α) Spot 46α antigen As a result of performing sequence identification by mass spectrometry for spot 46α, the amino acid sequence of SEQ ID NO: 554 was detected.

[0315] In addition, when the mass data obtained from a mass spectrometer for spot 46α was analyzed by comparing it with NCBI protein data, seed maturation protein PM22 (amino acid sequence: SEQ ID NO: 553, base sequence encoding it: SEQ ID NO: 552) was identified as a protein containing sequence number 554.

[0316] Therefore, in the present application, the antigen of spot 46α may be any protein selected from the group consisting of (46αA-a) to (46αA-e) and (46αB) below. (46αA-a) A protein comprising the amino acid sequence of SEQ ID NO: 553 in which one or more amino acids have been deleted, substituted, inserted or added. (46αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 553. (46αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 552 have been deleted, substituted, inserted or added. (46αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 552. (46αA-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 552. (46αB) A protein comprising the amino acid sequence shown in SEQ ID NO: 554. In this case, the amino acid sequence shown in SEQ ID NO: 554 may have one or several amino acids deleted, substituted, inserted or added.

[0317] The protein selected from the group consisting of (46αA-a) to (46αA-e) and (46αB) above may be a protein that appears as a spot with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the "Identification of Antigen" section above.

[0318] The epitope of the antigen of spot 46α is located at amino acids 112 to 120 (SEQ ID NO: 915) of SEQ ID NO: 553. The antigen of spot 46α may retain the sequence of SEQ ID NO: 553 for the amino acids at positions corresponding to the region of the epitope.

[0319] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 46α may be the following mutant.

[0320] Of the epitopes having the sequence of SEQ ID NO: 915, the site important for binding to IgE antibodies of allergy patients is the site represented by amino acids other than X in SEQ ID NO: 913 or 914. Therefore, in another preferred embodiment, the antigen of spot 46α is a site in which amino acids 112 to 120 in SEQ ID NO: 553 are the amino acid sequence of SEQ ID NO: 913 or 914. It may be something.

[0321] Preferably, the protein that is an antigen of spot 46α has activity equivalent to that of the protein having the amino acid sequence of SEQ ID NO: 553 (seed maturation protein PM22), or causes allergy to soybeans.

[0322] (47α) Spot 47α antigen As a result of performing sequence identification by mass spectrometry for spot 47α, the amino acid sequences of SEQ ID NOs: 557 to 563 were detected.

[0323] Furthermore, when the mass data obtained from the mass spectrometer for spot 47α was analyzed by collating it with the protein data of NCBI, it was identified as a protein containing either SEQ ID NO: 557 or 558, which is eukaryotic translation initiation factor 5A-2 (amino acid sequence: SEQ ID NO: 5 56, the base sequence encoding it: SEQ ID NO: 555), or uncharacterized protein LOC100305510 (amino acid sequence: SEQ ID NO: 560, the base sequence encoding it: SEQ ID NO: 559) was identified as a protein containing any of SEQ ID NOs: 561 to 563.

[0324] Therefore, in the present application, the antigen of spot 47α may be any of the proteins selected from the group consisting of (47αA1-a) to (47αA1-e), (47αB1), (47αA2-a) to (47αA2-e), and (47αB2). (47αA1-a) A protein comprising the amino acid sequence of SEQ ID NO: 556 in which one or more amino acids have been deleted, substituted, inserted or added. (47αA1-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 556. (47αA1-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 555 have been deleted, substituted, inserted or added. (47αA1-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 555. (47αA1-e) A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 555. (47αB1) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 557 and 558, preferably a protein comprising both of said amino acid sequences. In this regard, the amino acid sequence shown in either SEQ ID NO: 557 or 558 may have one or several amino acids deleted, substituted, inserted or added. (47αA2-a) A protein comprising an amino acid sequence in which one or several amino acids are deleted, substituted, inserted or added in SEQ ID NO: 560. (47αA2-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 560. (47αA2-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 559 have been deleted, substituted, inserted or added. (47αA2-d) A protein containing an amino acid sequence encoded by a base sequence that has an identity of 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more to the base sequence shown in SEQ ID NO: 559. (47αA2-e) consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 559 A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes to the nucleic acid under stringent conditions. (47αB2) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 561 to 563, preferably at least two or all of said amino acid sequences, wherein the amino acid sequence represented by any of SEQ ID NOs: 548 to 551 may have one or several amino acids deleted, substituted, inserted or added.

[0325] The protein selected from the group consisting of (47αA1-a) to (47αA1-e), (47αB1), (47αA2-a) to (47αA2-e), and (47αB2) may be a protein that appears as a spot with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 3.5 to 7.5, preferably 4.0 to 7.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0326] Furthermore, the epitopes of the antigens (47αA1-a) to (47αA1-e) and (47αB1) are located at amino acids 11 to 25 (SEQ ID NO: 916), amino acids 81 to 95 (SEQ ID NO: 917), and amino acids 131 to 145 (SEQ ID NO: 918) of SEQ ID NO: 556. When the antigen of spot 47α contains a mutation in the amino acid sequence of SEQ ID NO: 556, the sequence of SEQ ID NO: 556 may be retained for the amino acids at positions corresponding to at least one region of the epitope.

[0327] Preferably, the protein that is the antigen of spot 47α is a protein having the amino acid sequence of SEQ ID NO: 556 (eukaryotic translation initiation factor 5A-2) or a sequence It has activity equivalent to that of the protein having the amino acid sequence of sequence number 560 (uncharacterized protein LOC100305510), or causes soy allergy.

[0328] (48α) Spot 48α antigen As a result of performing sequence identification by mass spectrometry for spot 48α, the amino acid sequences of SEQ ID NOs: 566 to 570 were detected.

[0329] In addition, when the mass data obtained from the mass spectrometer for spot 48α was analyzed by comparing it with NCBI protein data, uncharacterized protein LOC100306570 (amino acid sequence: SEQ ID NO: 565, base sequence encoding it: SEQ ID NO: 564) was identified as a protein containing any of SEQ ID NOs: 566 to 570.

[0330] Therefore, in the present application, the antigen of spot 48α may be any protein selected from the group consisting of (48αA-a) to (48αA-e) and (48αB) below. (48αA-a) A protein comprising an amino acid sequence in which one or more amino acids are deleted, substituted, inserted or added in SEQ ID NO: 565. (48αA-b) A protein containing an amino acid sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the amino acid sequence shown in SEQ ID NO: 565. (48αA-c) A protein comprising an amino acid sequence encoded by a base sequence in which one or more nucleotides in SEQ ID NO: 564 have been deleted, substituted, inserted or added. (48αA-d) A protein containing an amino acid sequence encoded by a base sequence that is 70% or more, preferably 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, or 99% or more identical to the base sequence shown in SEQ ID NO: 564. (48αA-e) A nucleic acid consisting of a base sequence complementary to the base sequence shown in SEQ ID NO: 564 A protein comprising an amino acid sequence encoded by a nucleic acid that hybridizes under stringent acid conditions. (48αB) A protein comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 566 to 570, preferably a protein comprising at least two, three, four, or all of said amino acid sequences, wherein one or several amino acids may be deleted, substituted, inserted, or added in the amino acid sequence represented by any of SEQ ID NOs: 566 to 570.

[0331] The protein selected from the group consisting of (48αA-a) to (48αA-e) and (48αB) above may be a protein that appears as a spot with a molecular weight of 2 to 50 kDa, preferably around 5 to 40 kDa, and an isoelectric point of 3.5 to 8.5, preferably 4.0 to 8.0, in a gel when two-dimensional electrophoresis is performed under the conditions described in the above section "Identification of antigen."

[0332] The epitope of the antigen of spot 48α is located at amino acids 94 to 102 (SEQ ID NO: 921) and amino acids 131 to 145 (SEQ ID NO: 922) of SEQ ID NO: 565. The antigen of spot 48α may retain the sequence of SEQ ID NO: 565 for the amino acids at positions corresponding to the region of the epitope.

[0333] Furthermore, from the viewpoint of improving sensitivity (degree to which a patient can be judged as positive) and specificity (degree to which a healthy person cannot be judged as positive), the antigen of spot 48α may be the following mutant.

[0334] Of the epitope having the sequence of SEQ ID NO: 921, the site important for binding to IgE antibodies from allergy patients is the site represented by amino acids other than X in SEQ ID NO: 919 or 918. Therefore, in another preferred embodiment, the antigen of spot 48α may be one in which amino acids 94 to 102 in SEQ ID NO: 565 are the amino acid sequence of SEQ ID NO: 919 or 918.

[0335] Preferably, the protein that is an antigen of spot 48α has activity equivalent to that of the protein havi...

Claims

1. A soybean-derived antigen that specifically binds to IgE antibodies of allergic patients, comprising: (4β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 719, 721, 722, 724 to 731; (7β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 741 and 744; (9β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 747 to 749; (13β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 757, 758; (14β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 759 to 761, 763, and 764; (27β) a polypeptide comprising the amino acid sequence of SEQ ID NO: 820; (34β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 842 to 846; (39β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 893 to 895; (42β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 905 and 906; (52β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 933 to 938; (54β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 940 and 943; The antigen is any one of the following:

2. A soybean-derived antigen that specifically binds to IgE antibodies of allergic patients, (22β) a polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 803 to 808; The antigen,

3. The antigen according to claim 1 or 2, which has 500 or less amino acid residues.

4. A kit for diagnosing allergies, comprising at least one of the antigens according to any one of claims 1 to 3.

5. A composition for diagnosing allergies, comprising at least one of the antigens according to any one of claims 1 to 3.

6. 1. A method for providing an indicator for diagnosing allergy in a subject, comprising the steps of: (i) contacting a sample obtained from a subject with an antigen, wherein the sample is a solution containing Ig antibodies; (ii) detecting binding of IgE antibodies to the antigen in a sample obtained from the subject; (iii) if binding of the subject's IgE antibodies to the antigen is detected, an indication that the subject is allergic is provided; wherein the antigen is at least one of the antigens according to any one of claims 1 to 3.

7. A pharmaceutical composition comprising at least one antigen according to any one of claims 1 to 3.

8. The pharmaceutical composition according to claim 7 for treating allergies.

9. A tester for determining the presence or absence of an antigen in a subject, comprising an antibody that binds to at least one of the antigens according to any one of claims 1 to 3.

10. A method for producing an edible processed product in which an antigen has been removed or reduced, or a polypeptide has been cleaved or removed, the method comprising a step of confirming that the antigen has been removed or reduced, or the polypeptide has been cleaved or removed, during the production of the processed product, wherein the antigen is at least one of the antigens described in any one of claims 1 to 3, and the polypeptide is at least one polypeptide that is an antigen described in any one of claims 1 to 3.

Images